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Everything habitual draws around us an ever firmer net of spider-webs; and soon we 
notice that the threads have become cords and that we ourself are sitting in the 
middle as the spider who has caught himself and has to live on his own blood. That 
is why the free spirit hates all habituation and rules, everything enduring and 
definitive, that is why he sorrowfully again and again rends apart the net that 
surrounds him: even though he will as a consequence suffer numerous great and 
small wounds - for he has to rend those threads from himself, from his own body and 
soul. 
F. Nietzsche 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
                               
 
List of abbreviation 
 
PD: Parkinson’s Disease 
PSP: Progressive Sopranuclear Palsy 
NMS: Non-motor symptoms 
CI: cognitive impairment 
NPS: neuropsychiatric symptoms  
ICDs: Impulse Control Disorders 
DAs: dopamine agonists 
DRT: dopamine replacement therapy 
PDD: Parkinson’s Disease Dementia 
DLB: Dementia with Lewy bodies DLB 
PIGD: postural instability gait disorder 
PDQ-39: The Parkinson's Disease Questionnaire-39 
MCI: Mild Cognitive Impairment 
LBs: Lewy Bodies 
UPDRS-III: Unified Parkinson’s Disease Rating Scale–Part III  
H&Y: modified Hoehn and Yahr scale  
PET: Positron emission tomography PET 
SPECT: single photon emission computed tomography  
MRI: magnetic resonance imaging 
fMRI: functional magnetic resonance imaging  
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1. Introduction 
1.1 Non-motor symptoms of PD 
A consistent body of epidemiological, pathological, and clinical evidence suggests that PD 
can no longer be considered as only a complex motor disorder characterized by 
extrapyramidal symptoms, but rather as a progressive multisystem disease—or more 
properly, multiorgan disease—with several motor and non-motor symptoms [1].  
Indeed, in the last years it has been clear that person affected by PD experience a wide 
range and nature of non-motor symptoms from gastrointestinal to sleep disorders, from 
dysautonomia to cognitive problems, from apathy to depression either occurring in 
isolation as the dominant feature or in combination [2]. To make the all picture even more 
complex, growing evidence established that PD can be divided into a preclinical phase 
(supported by molecular or imaging markers), a premotor/prodromal phase (with non-
motor symptoms) and the motor phase, the ‘tip of the iceberg’ [3] [Fig 1.1]. 
Therefore, while some non-motor symptoms dominate in the early or even in the 
‘premotor’ phase of PD [4], others complicate the clinical picture throughout the disease 
(pain, fatigue) and especially in its advanced stages (dementia, apathy, dysautonomia), as 
shown in the Sydney multicenter study [5] report at 20 years. In addition, some NMS are 
related to drug therapy.  
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Fig 1.1 Adapted from The prediagnostic phase of Parkinson's disease. Noyce AJ, Lees AJ, Schrag AE. J Neurol Neurosurg 
Psychiatry. 2016. A schematic showing determinants of risk, the prediagnostic phase (preclinical and prodromal phases) 
and clinical phase of PD, along with the parallel application of risk and disease progression markers to measure disease 
activity across phases. 
 
1.1.1 Pathogenesis of NMS 
The traditional concept that the first neuropathological insult leading to PD is the 
degeneration of neuromelanin-containing neurones in the pars compacta of the substantia 
nigra (resulting in depleted levels of the dopamine) has been challenged. Many studies, 
spearheaded by the Braak theory [6, 7], suggest that a non-dopaminergic process is key to 
the non-motor symptoms of PD, many of which start well before the motor Parkinson’s 
features emerge, and give clear evidence of differential neuronal degeneration involving 
several neuropeptide pathways in the brain in PD [8]. 
The well-known theory of Braak [6, 7] indicates that the pathological landmark of PD, the 
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Lewy bodies, can be identified in several neuronal populations other than the 
dopaminergic mesencephalic ones [9]. Following the ascending gradient of neuronal 
involvement throughout disease progression, six neuropathological stages of PD have 
been identified [7] [Fig. 1.2].  
  
 
Fig 1.2. The Braak stages of PD. Adapted from:: Doty RL (2012) Nature Reviews Neurology 8, 329-339. 
 
In stages 1 and 2, defined as “presymptomatic stages”, the Lewy bodies are confined to 
the anterior olfactory nucleus, olfactory bulb, dorsal motor nucleus of the 
glossopharyngeal and vagal nerves, locus coeruleus, and reticular formation. In stages 3 
and 4 (“intermediate stages”), the neuropathological damage extends to the substantia 
nigra pars compacta, other mesencephalic nuclei, the prosencephalon and meso-
allocortical regions; during these stages, the motor symptoms develop and progressively 
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worsen. Eventually, in stages 5 and 6 (“advanced stage” of PD), neocortical, prefrontal, 
and associative cortices are pathologically involved; in these latter stages, severe motor 
disturbances are accompanied by cognitive and behavioral symptoms.  
Despite Braak staging does not provide an overall explanation for all NMS and premotor 
findings, it is still helpful in understanding the pathogenesis of NMS when combined with 
a broader view of PD as being more than merely a disorder of dopamine deficiency in the 
brain [10]. Indeed, clinically, NMS comprise a range of clinical signs and symptoms 
resulting from multiple neurotransmitter deficiencies and differential rates of 
neurodegeneration within the central and peripheral nervous systems as well as the gut 
from the colon-rectum to the salivary glands [2, 11-13] [fig 1.3]. Nevertheless, the clinical 
diagnosis of PD rests on the identification of the characteristics related to dopamine 
deficiency that are a consequence of degeneration of the substantia nigra pars compacta.   
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Fig 1.3. Adapted from: Nonmotor Subtyping in Parkinson’s Disease Anna Sauerbier, Miguel Rosa-Grilo, Mubasher A. 
Qamar, K Ray Chaudhuri. Int Rev Neurobiol. 2017;133:447-478 1.1.2 The breadth of the issue: the impact of NMS 
 
NMS are prevalent in over 90% of people with PD from untreated stage to advanced [14-
18]. As the average age and life expectancy of the population increases, and given that PD 
is the second most common neurodegenerative disorder, the non-motor features of PD 
become increasingly important [19, 20]. Indeed, despite the emphasis on motor 
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symptomatology, several studies have shown that the non-motor symptoms of PD, such as 
depression, psychosis, falls, and sleep disturbance, have greater significance when 
assessed by quality-of-life measures, institutionalization rates, or health economics [21-
28]. “The Sydney Multicenter Study of Parkinson’s Disease”, a prospective study of patients 
with PD followed up for 15–18 years, describes the role and effect of the NMS complex 
during the disease course and shows that non-levodopa responsive non-motor symptoms 
are the most disabling feature of the disease [20]. In particular, the major causes of 
disability in patients surviving for 15 or more years were falls, autonomic disturbance, 
neuropsychiatric symptoms, and dementia, aspects of the disease that are not improved 
by L-dopa. Falls occurred in 81% of patients, and 23% sustained fractures. Cognitive decline 
was present in 84%, and 48% fulfill the criteria for dementia. Hallucinations and depression 
were experienced by 50%. Choking has occurred in 50%, symptomatic postural 
hypotension in 35%, and urinary incontinence in 41% [20]. Accordingly, the PRIAMO study 
[29] found that nearly all patients with PD reported at least one NMS, with fatigue and 
anxiety being the most frequent. In particular, the psychiatric symptoms were the most 
frequently reported (66.8% of the sample), followed by sleep (64.1%), gastrointestinal and 
pain (61.0%), fatigue (58.1%), urinary (57.3%), and attention/memory (44.7%). Moreover, 
they reported that apathy was the symptom associated with worse PDQ-39 score but also 
presence of fatigue, attention/memory, and psychiatric symptoms had a negative impact 
on quality of life. 
In a survey by the leading UK Parkinson's charity, Parkinson's UK, members rated 
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symptoms such as sleep disturbance, pain, constipation, urinary problems and dizziness to 
be as debilitating as and possibly more intrusive than their motor symptoms [30, 31]. 
This evidence demonstrates that NMS have a greater impact on health-related quality of 
life than do motor abnormalities, even early in the course of PD. Other studies have 
documented that NMS, specifically hallucinations, are the strongest predictor of nursing 
home placement for persons with PD. In the nursing home setting, NMS appear to be 
virtually universally present in patients with PD; individuals typically display multiple types 
of NMS, which occur with great frequency [32]. In persons with PD living at home, NMS in 
the form of neuropsychiatric symptoms also are important determinants of caregiver 
burden.  
PD decreases quality of life for patients and imposes a significant economic burden on 
society comparable with other chronic diseases, such as congestive heart failure, diabetes, 
and stroke [33, 34]. A UK based cost analysis estimated that an annual direct cost of £4189 
per year for PD managed at home rises to £19 338 for full-time institutionalization [26]. 
Although the importance and impact of NMS, they are often no recorder in clinical 
consultations. An international survey in 2010 showed that in up to 62% of cases, NMS of 
PD such as apathy, pain, sexual difficulties, bowel incontinence, and sleep disorders might 
remain undeclared to the health care professionals because the patients are either 
embarrassed or unaware that the symptoms are linked to PD [35]. 
In light of the importance and impact that NMS hold for persons with PD and for their 
family, it is vitally important that physicians caring for them are familiar with and are 
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attentive to diagnosing NMS when they occur. 
With this in mind, NMS have now been incorporated in the new published diagnostic 
criteria for PD and in particular prodromal Parkinson’s [36, 37]. 
 
1.2 Overview of neuropsychiatric symptoms in PD 
NPS and cognitive symptoms occur in nearly all PD patients and may surpass motor 
symptoms in their impact on quality of life. NPS are identified to be integral to PD 
throughout the course of the disease, often developing in the early, untreated stages, 
before the onset of classical motor symptoms of PD [38-42]. Indeed, mood symptoms such 
as apathy, depression, and anxiety are common in PD and may precede the onset of motor 
symptoms by many years [4, 43, 44]. The concept of mood symptoms as a pre-motor stage 
of PD is consistent with the neuroanatomical staging system proposed by Braak and 
colleagues, who demonstrated early accumulation of alpha-synuclein within brainstem 
structures, followed by rostral spread into the midbrain, basal ganglia, and, eventually, the 
cortex [6, 45]. Following this pattern, dysfunction within the dorsal raphe nucleus and 
locus coeruleus may disrupt serotonergic and noradrenergic systems and may occur before 
significant loss of dopaminergic cells within the substantia nigra results in overt motor 
symptoms [46, 47]. Dysfunction in the dopaminergic system also contributes to the 
development of mood symptoms in PD, and the symptoms may vary both with the chronic 
dysfunction of the system and with fluctuating serum levels of levodopa or dopamine 
agonists [48]. 
                                         C. Pellicano – Neuropsychiatric and Cognitive symptoms in PD 
 
 
 ______ 
  14 
 
In contrast, other neuropsychiatric symptoms such as cognitive dysfunction, dementia, 
and psychosis are more common in later stages of the disease and with the effect of DRT. 
Particularly dopamine agonists that cause hyperdopaminergic states, has been associated 
with psychosis, ICDs, excessive daytime sleepiness, and hallucinations. 
 
1.2.1 Depression 
Depression is the most common mood disorder in PD and is more common than in age-
matched controls in other chronic diseases, such as diabetes, hypertension, coronary 
artery disease, or congestive heart failure [44, 49-52]. The estimated prevalence of 
depression varies widely between studies, and depressive symptoms have been reported 
in up to 90 % of patients [51]. Due to the broad spectrum of depressive symptoms, the 
types of depressive disorder considered in the studies influence the prevalence.  
A systematic review in 2015 estimated that 50–70 % of patients with PD had been affected 
by symptoms of depression [53], while others report that 35 % had clinically significant 
depressive symptoms and 17% met criteria for major depressive disorder. Depression in 
PD typically shows an elevated degree of dysphoria and irritability, pessimism about 
future, with low levels of inadequacy and sense of guilt [54].   
A significant biological rather than a pure reactive basis for depression associated with PD 
is probable and could, in part, be the result of damage to serotoninergic 
neurotransmission as well as limbic noradrenergic and dopaminergic mechanisms [2]. 
Studies have suggested that symptoms of depression may precede the diagnosis of PD 
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from 5 up to 20 years [4, 2, 41, 43, 55] years and that depression is associated with an 
increased risk of developing clinical PD with an incidence of 23% [56]. 
Notably, some patients experience symptoms of depression that emerge or worsen during 
off periods, when serum (and presumably brain) levels of dopaminergic medication are 
lower and the parkinsonian motor features are inadequately treated [47]. 
 
1.2.2 Anxiety  
Anxiety is the second most common affective disorder in PD, with an estimated 40–50 % 
of patients experiencing clinically significant symptoms of anxiety, and approximately one 
third of patients meeting diagnostic criteria for anxiety disorder [57-59]. Anxiety disorders 
can also be a preclinical risk factor [41, 60]. Anxiety syndromes in PD include generalized 
anxiety, social phobias, specific phobias (including fear of off periods or freezing), and 
panic attacks; the symptoms are frequently co-morbid with depression [57-59]. Anxiety 
symptoms may be present throughout the day but are frequently encountered during off 
periods of insufficient motor control, or during the transition from on to off periods. 
Similar to depression, it is essential to screen for anxiety symptoms that vary with motor 
symptoms, and to adjust dopaminergic medications to limit or prevent off periods and 
motor fluctuations. 
 
1.2.3 Apathy  
Apathy, defined as a lack of feeling, emotion, interest, concern and reduced energy, has 
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now been established as a distinctive symptom of PD independent of depression, 
somnolence, and fatigue [61, 62]. Indeed, apathy ranges from 17 to 70 % of PD patients 
[61-65] and affects 20– 40 % of PD patients without dementia, and up to 60 % of patients 
with PD and dementia after 5–10 years [66-68]. Further, studies reported on prevalence 
of apathy in treatment-naïve PD patients [38, 69, 70].  
Patients with PD have higher levels of apathy than do equally disabled patients with 
osteoarthritis, which indicates a neurodegenerative contribution [71]. Negative symptoms 
such as apathy, anhedonia, and fatigue could be due to neuronal degeneration in areas 
that mediate goal directed behavior (i.e., frontal-subcortical areas) or reward centres (i.e., 
dopaminergic projections between the ventral tegmentum and nucleus accumbens) [72, 
73]. The features of apathy in the disease respond only slightly to dopaminergic drugs, 
possibly indicating more extensive contributions from other neurotransmitter pathways. 
Apathy shares many symptoms with depression, including loss of interest in goal-directed 
behaviors and emotional blunting, but is differentiated by the relative absence of mood 
symptoms. Apathy is also correlated with worsening cognitive impairment, is a predictor 
of further cognitive decline and dementia [74, 75] and it is a major cause of caregiver 
distress [76]. 
 
1.2.4 Anhedonia 
Anhedonia, defined as “the inability to experience pleasure” from activities usually found 
enjoyable on bases of subjective emotional experience for positive and negative events 
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[77, 78], is a key symptom of depression and of apathy in PD patients. In this definition, 
the focus is on the subjective emotional experience of the patient and not on 
interpersonal behavioral aspects. Anhedonia is generally seen as a symptom and not a 
syndrome [79]. As a symptom, it may be part of the syndrome of apathy, following the 
criteria of Marin and their subsequent revisions [81-82]. It is also considered part of major 
depressive disorder, and of the negative syndrome of schizophrenia [83]. The prevalence 
of anhedonia in PD patients varies from 10 to 40% [84, 85]. The association between 
anhedonia, apathy, and depression is intricate because the diagnostic criteria are unclear 
and there are overlaps of symptoms between these neuropsychiatric disorders. Several 
studies highlighted a correlation between anhedonia and depression, proving that PD 
patients with depression showed higher levels of anhedonia than PD patients not 
depressed [85-87]. Lemke et al., [86] reported that the frequency of anhedonia in PD 
(N=657) ranged about the 45,7% of all sample and the 79,7% of depressed subjects. In 
contrast, other authors [88] showed no significant correlation among anhedonia, 
depression and apathy. The impact of anhedonia on motor symptoms and quality of life 
has hardly been studied. 
 
1.2.5 Alexithymia 
Alexithymia, mainly defined as the inability to symbolize or mentalize emotions [89], is a 
fairly common phenomenon in PD (ranged from 18 to 23.8%) and it seems related to the 
severity of depression symptoms in PD patients [90]. Particularly, Costa et al., [91] 
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reported that alexithymia was significantly more severe in patients with major depressive 
disorder (MDD) than in patients with minor depressive disorder (MIND) and without 
depression (NODEP). Assogna et al. [92] reported an alexithymia prevalence rate of about 
50% in PD patients with MDD and 25% in patients with MIND. However, previous studies 
[93, 94] proposed that depression symptomatology does not predict and does not 
completely explain the presence of alexithymia in PD, suggesting that depression and 
alexithymia may be partially overlapping but independent affective disorders [89, 95]. 
In a small controlled study, Poletti et al. estimated [93] that 23.8% of the de novo PD 
patients are alexithymic, 26.2% borderline alexithymic, and 50% non-alexithymic. These 
percentages were not statistically different compared with controls. On the other hand, 
they observed that de novo PD with the postural instability gait difficulty motor subtype 
presented more alexithymic features than PD patients with tremor-dominant phenotype, 
suggesting that the postural instability gait difficulty subtype could represent a risk factor 
for developing alexithymia [95]. 
 
1.2.6 Psychosis  
Psychosis affects more than 50 % of patients with PD at some time, and may affect up to 
75%of patients with PDD [20,97,98]. Psychotic symptoms are frequently caused or 
worsened by anticholinergic or dopaminergic treatment, particularly with dopamine 
agonists, but also occur in untreated PD [98, 99]. The results of the PRIAMO study [100], 
assessing psychosis in early PD patients (H&Y score ≤ 2, disease's duration (median) 3.4 
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years), reported that the prevalence of psychotic type symptoms at baseline was 3%; the 
incidences at 12 and 24 months were 5.2% and 7.7%, respectively. The development of 
psychosis over the 24-month period was associated with longer disease duration and 
prescription of dopamine agonists at baseline.  
Psychotic symptoms in PD have been related to Lewy body pathology affecting the 
temporal lobes and causing diffuse cortical cholinergic dysfunction, and to serotonergic 
dysfunction with increased serotonin-2A (5HT2A) receptor binding potential in multiple 
areas including visual processing areas and prefrontal cortex [101]. Although visual 
hallucinations are commonly viewed as a side effect of treatment for PD, neuronal 
degeneration of the pedunculo pontine nucleus, locus coeruleus, and the dopaminergic 
raphe nuclei might be causative [102]. 
Symptoms range from mild visual distortions and the sense of presence to fully formed, 
complex hallucinations. Visual images of people or animals are the most common type of 
hallucination, although other sensory modalities may also be affected. Auditory 
hallucinations have been reported in 8%of patients with PD psychosis, but predominant 
auditory symptoms such as those seen in schizophrenia are uncommon [103]. Grandiose, 
religious, and/or persecutory hallucinations are also rare in PD psychosis. PD psychosis is 
also distinct from delirium, as the psychotic symptoms occur without significant change in 
baseline cognition. Delirium can occur in advanced dementia or can be induced by 
concurrent infection or dopaminergic drugs. Sudden drug withdrawal can precipitate a 
parkinsonism hyperpyrexia or neuroleptic malignant syndrome, which may be associated 
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with delirium [104]. Delusions are less common in PD and affect a subset of 5 30 % patients 
[20, 96], but these fixed beliefs are often refractory to treatment. Psychotic symptoms 
strongly correlate with the need for decline in cognitive performances, nursing home 
placement and with mortality [105].  
  
1.2.7 Impulse Control Disorders  
ICDs include pathologic gambling, compulsive buying, hyper-sexual behavior, and binge 
eating [106]. Hobbyism, a compulsive over-interest in other activities such as collecting 
items or following sports scores, may also occur. These behaviors vary widely in severity 
but can have devastating financial and social consequences for patients and families. ICDs 
occur most frequently in patients using DAs, although they are also reported in patients 
using levodopa [107]. A cross-sectional study of 3090 patients with PD found that 17 % of 
patients using a DA demonstrated an ICD during 6 months of treatment, versus 7 % of 
patients not on a DA [107]. Longitudinal studies have found even higher prevalence, with 
nearly 40%of patients receiving DA therapy developing an ICD during 4 years of treatment 
[108, 109]. The risk for developing ICD appears to increase with higher doses of 
dopaminergic medications, although they can occur even at low doses. Other risk factors 
include younger age, male sex, cigarette smoking, history of substance abuse, and history 
of impulsive behaviors [106, 110]. The oral DAs pramipexole and ropinirole appear to 
impart similar risks for developing ICD, and it is unclear whether the use of extended 
release oral formulations decreases these risks. In contrast, a cross-sectional study of 
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patients using oral DA versus transdermal rotigotine did find a significant reduction in ICD 
with rotigotine, with 42 % of patients on oral pramipexole or ropinirole meeting criteria 
for ICD based on the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s 
disease Rating Scale (QUIP-RS), versus 19 % of patients on transdermal rotigotine [111]. 
Adjunctive use of rasagiline was also associated with an increased risk for ICD in this study, 
as well as in isolated case reports [112]. 
 
1.2.8 Cognitive Dysfunctions and Dementia in PD 
The neuropsychological deficits in PD range from mild executive dysfunction in the early 
stages to MCI and dementia in the later stages (Table 1.1). Cognitive impairment is 
common, with up to 50 % of PD patients showing deficiencies in one or more cognitive 
areas within 5 years of diagnosis [113]. In newly diagnosed untreated patients with PD, 
cognitive impairment ranges from 18% to 36% of incident cohorts [38]. Affected domains 
include psychomotor speed, memory, executive function, visuospatial skills, and 
attention, while language appears to be less affected. Cognitive deficits have also been 
divided into frontal and posterior types. It has been proposed that deficits reflecting 
cognitive dysfunction in more posterior parts of the brain such as semantic fluency or 
visuospatial deficits carry a worse cognitive prognosis [114].  
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Table 1.1. Cognitive deficits and example of tests used in diagnosis 
ToL Tower of London test; SoC Stocking of Cambridge (both from CANTAB [Cambridge Neuropsychological Test 
Automated Battery]); WCST Wisconsin Card Sorting Test; CVLT California Verbal Learning Test; RAVLT Rey’s Auditory 
Verbal Learning Test; VH visual hallucinations 
 
1.2.8.1 Executive functions  
Executive function refers to a set of cognitive processes that control goal-directed 
behaviours from goal formulation and intention formation to successful execution and 
processing of the outcome [115]. Impairment of executive functions constitutes the core 
feature of neuropsychological dysfunction in PD patients and can be present from the 
early stages [116-118]. Executive dysfunction in PD is characterized by deficits in internal 
control of attention, set shifting, planning, inhibition, conflict resolution, impairment in 
dual task performance, and on a range of decision-making and social cognition tasks [115]. 
These impairments are similar, but not identical [119] to those seen in patients with 
Cognitive Domain  Description of cognitive deficit  
Examples of neuropsychological 
tests 
Executive Functions 
↓↓ verbal fluency, ↓ set-shifting, planning & 
concept formation; may influence memory functions  
Verbal fluency (semantic & 
phonemic); ToL/SoC (CANTAB); 
WCST; Stroop  
Visuospatial & 
constructural 
function 
Globally impaired visual perception (predisposes to 
VH); impaired size and form discrimination; ↓ face 
recognition; marked impairment on clock-drawing 
test  
Clock-drawing test; Benton’s 
judgement of line orientation  
Memory  
Episodic memory less affected than AD; ↓ visual & 
verbal memory; recall > recognition affected early 
on  
Free and cued recall, e.g. CVLT or 
RAVLT  
Attention & Working 
Memory 
Fluctuating alertness; auditory and visual attentional 
deficits  
Digit span; Trail Making Test  
Language  
Less impairment than AD; less affected until severe 
disease  
Boston naming test  
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frontal lesions and are thought to represent a dysfunction of the fronto-striatal neuronal 
circuitry [120, 121].  
Indeed, the dopaminergic neurons in the posterior putamen, which are severely affected 
in PD, are particularly relevant for the execution of automatic behaviours. It has been 
suggested that PD patients compensate by relying on non-routine action control mediated 
by the relatively preserved rostromedial striatum. Consequently, due to basal ganglia 
dysfunction, PD patients need to exert cortical executive control even for routine tasks, 
which healthy individuals perform automatically [115]. 
Executive deficits in PD are related to depression and apathy, postural instability, freezing 
of gate, and other gait problems [122-124]. 
Different executive functions are affected to different degrees and at different stages of 
PD. Attentional set shifting is compromised earlier than planning, and the decline in spatial 
working-memory is faster or more severe than for other forms of working memory [115]. 
The predictors for a more pronounced decline are male gender, older age, and later onset 
of disease. The progressive executive and general cognitive decline in PD reflects the 
increasing involvement of other non-dopaminergic neurotransmitter systems such as the 
cholinergic system [125]. 
 
1.2.8.2 Visuospatial abilities  
Visuospatial impairment has been described in patients with PD [126, 127], even when 
tests reveal few motor component involvement [128]. In non-demented patients with 
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mild to moderate PD visual impairment has been found to correlate with impairments in 
cognition (i.e. executive functions and verbal memory), postural control and gait, and 
functional disability [129]. Furthermore, visuospatial impairment was found to be more 
severe in patients with PD and dementia (PDD) than in AD patients with an equivalent 
severity of dementia [130-133]. It has been suggested that such visuospatial impairment 
may be at least partly attributable to frontal-executive dysfunction in addition to deficit in 
temporal and parietal cortices. 
 
1.2.8.3 Memory  
Memory impairment has frequently been reported in PD and is characterized by poor free 
recall and relatively better recognition. Impaired immediate and delayed recall can largely 
be remedied by semantic cueing or probing [117,134] suggesting that the memory deficits 
in PD may be due to retrieval problems [135-137], as opposed to the deficient encoding 
seen in Alzheimer Disease [138-140]. This may reflect a deficiency in internally-cued 
search strategies due to the dysexecutive syndrome [141]. However although a frontal-
type memory impairment is the most common memory profile in PD, impairment of both 
recall and recognition, a pattern similar to that found in AD [142] has been found. This 
finding suggests that hippocampal pathology [143, 144] may also contribute to memory 
impairment in a subgroup of patients with PD. 
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1.2.8.4 Attention  
Attentional dysfunction is prominent among the cognitive impairments described in PD 
and is probably closely related to the executive function impairment reported in these 
patients. This hypothesis is supported by several studies showing that attentional 
dysfunction appears most usually in connection to complex tasks requiring shifting and/or 
sustained attention [145, 146], as well as mental calculations that require sustained 
mental tracking [147]. Attentional dysfunction is a characteristic feature of PDD and DLB, 
and consists both of reduced and fluctuating performance [148]. The underlying 
pathological substrate of this dysfunction seems to underlie on metabolic activity [149] 
and cholinergic deficits in the thalamus [150]. 
 
1.2.8.5 Mild Cognitive Impairment and Dementia  
A task force of the Movement Disorder Society (MDS) [151] has recently outlined the 
diagnostic criteria for MCI in PD.  
Single-domain PD-MCI was initially divided into amnestic and nonamnestic subtypes. 
More recently, single-domain PD-MCI has been subdivided based on the cognitive domain 
impaired without preferential reference to amnestic deficits [152]. Executive deficits are 
particularly common in single-domain PD-MCI [152], justifying the departure from the 
amnestic/nonamnestic distinction that had been borrowed from experience with MCI in 
the general population. 
MCI can include executive dysfunction and impairment of attention and working memory, 
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as well as deficits confined to language, memory, or visuospatial domains. MCI is a 
predictor of dementia in PD, which in the long term develops in up to 80% of patients [5, 
137, 153]. Indeed, most patients who develop PD-MCI will progress to dementia within 5 
years [154], and over 80% of patients surviving 20 years after diagnosis of PD will have 
dementia [5]. 
An MDS task force [155] has also outlined the diagnostic criteria for dementia in PD. 
Impairment of executive functions, particularly word fluency, has been found to be a 
predictor of later development of dementia [156-158]. Dementia occurs in up to 40% of 
people with PD, a rate about six-times higher than that in healthy individuals [159]. 
Dementia is progressive and is clinically characterized by a dysexecutive syndrome with 
impairment of visuospatial abilities and memory on a background of loss of response to 
dopaminergic drugs including levodopa [160, 161]. Degeneration of nigral cells is 
implicated, and although presence of cortical and subcortical Lewy bodies is also likely to 
be causative, this link is controversial [162, 163]. Cholinergic cell loss in the nucleus basalis 
of Meynert is prominent in PD and forms the basis of cholinergic treatment for dementia 
in the disease. Patients with PDD exhibit greater cortical cholinergic deficits than those 
with Alzheimer’s dementia (AD) [164]. 
The contribution of comorbid Alzheimer’s disease and vascular pathology, as well as a 
possible genetic association with the APOE genotype, have also been implicated. 
Hippocampal volume, as detected by volumetric MRI studies, is diminished in PD with 
dementia to a similar extent to that in Alzheimer’s disease [165]. 
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1.3 From One to the Many: redefining PD 
The amount of new knowledge the research brought about in last years is of such a 
breadth to break through the boundaries among PD as currently defined. The possible 
collapse of those very boundaries urges then the medical community to forge new 
categories, to better explain and better heal PD. In recognition of the profound changes 
in our understanding of PD, the International Parkinson and Movement Disorders Society 
(MDS) commissioned a task force to consider a redefinition of PD [166]. 
PD is a remarkably variable condition and beyond the complexity of its clinical 
manifestations, there is also a wide heterogeneity at individual level. PD varies in clinical 
features, dominant symptoms, and rate of progression from case to case. This variability 
has prompted a number of studies investigating the existence of PD subtypes, which divide 
PD patients into groups based on clinical or demographic features [167]. 
Recently the National Institutes of Health established subtype identification as one of the 
top three clinical research priorities in PD [168]. Indeed, identification of distinct PD 
subtypes is of great priority to shed light on underlying pathophysiology, predict 
progression and develop more efficient personalized care approaches.  
There is currently no clear way to define and divide subtypes in PD. Many different 
groupings or subtype classification systems have been proposed, which raises questions 
about which are most useful and their implications for future research. Furthermore, the 
progressive nature of PD makes it important to consider the possibility that subtypes may 
                                         C. Pellicano – Neuropsychiatric and Cognitive symptoms in PD 
 
 
 ______ 
  28 
 
differ with disease duration, and that the relationship of specific symptoms to subtypes of 
PD may be different across the course of the disease. Two main approaches to deriving 
subtype classifications have been used: empirical classifications based on clinical 
observation of the heterogeneity of PD and data-driven classifications with cluster analysis 
to identify subtypes in a hypothesis-free manner. Data-driven cluster analysis has the 
potential advantage of a hypothesis-free approach, allowing broader interrogation of the 
features and unbiased estimates of factor importance [166, 168-170].  
The first approach classifies subgroups on a single factor and looks for differences 
between groups. Two commonly suggested subtypes are onset age and tremor 
dominance. Age subtyping is proposed because young patients have more robust L-dopa 
response, more motor complications, and fewer cognitive disturbances [171-173]. Tremor 
predominant subtypes are proposed because they may have better prognosis and fewer 
cognitive disturbances [171-173] Other studies suggest other potential subtype 
identifiers; for example, olfactory loss correlates with cognitive impairment [174], and 
RBD correlates with autonomic dysfunction and higher dementia risk [175, 176]. 
Few studies have examined the influence of side and type of motor signs at disease onset 
and the presence of nonmotor PD symptoms. Some results indicated that patients with 
right-sided, tremor-dominant symptoms showed relative sparing of cognitive function 
[177, 178]. Conversely, Viitanen et al, found no association between side and type of 
motor signs at disease onset and cognitive impairment [179]. Baumann and collegues 
[180] reported faster motor progression in patients with a right-sided onset. However, 
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data on on the association of specific motor and nonmotor manifestations are rather 
contradictory. In the future, it may also be possible to subdivide PD according to 
pathogenic mechanism (mitochondrial predominant, inflammatory predominant, and so 
on). 
In the second approach, clusters have been defined based on age, motor features, and, 
possibly, a non-motor symptom cluster. These variables correlate with different mortality, 
progression, motor complications, dementia, and behavioral symptoms [171]. 
The etiological and physiological bases of this heterogeneity are, however, very poorly 
understood. The mechanism for subtype differences is unclear. Potential explanations 
include the variability in comorbid pathology (eg, subtle Alzheimer pathology interacting 
with synuclein in the cortex), the relative vulnerability of substantia nigra (if “mainly 
motor” patients have more vulnerable nigral neurons, then they may present earlier with 
pure motor symptoms), or perhaps even the variable propensity for synuclein pathology 
to spread from region to region [181]. 
Efforts to define subtypes of PD attempt to provide a framework for studying this 
heterogeneity. 
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Fig 1.4. Approach to subtyping in PD. Adapted from Marras, C., & Chaudhuri, K. R. (2016). Nonmotor features of 
Parkinson’s disease subtypes. Movement Disorders, 31(8), 1095–1102 
 
1.3.1 Motor dominant subtypes of PD 
The most commonly used empirically defined subtyping system divides patients into 
tremor-dominant or nontremor-dominant subtypes. Non tremor-dominant PD has been 
characterized as either akinetic-rigid or postural instability gait disorder (PIGD) 
phenotypes and sometimes a third, ‘indeterminate’ group [182]. Akinetic/rigid subtype 
overlaps with the previously known PIGD-dominant subtype [183] since it has been 
defined to describe a group of tremor-free patients with significant axial rigidity. Patients 
are easily classified in this system based on Unified Parkinson’s Disease Rating Scale scores 
or MDS-UPDRS scores: PIGD and tremor scores can be calculated using their UPDRS-part 
Subtyping in PD
Empirical 
classification 
(clinical 
observations) 
Motor Non-motor
Cognitive
Non-motor non 
Cognitive (i.e., 
hyposmia, sleep, 
autonomic)
Age at onset
Data-driven 
classifications 
(hypothesis-free 
approach)
Usually
multidimensional
cluster
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III items. Overall, it does seem that tremor-predominant subtype at onset has a more 
benign course of disease and slower progression that PIGD-dominant subtype [184]. 
Conversly, PIGD-dominant phenotype is associated with faster cognitive decline [185, 
186], higher prevalence of depression and apathy [187], more hyposmia [188], higher 
prevalence of other NMS [189], and overall faster progression [182, 190]. Imaging and 
biomarkers studies corroborate such a difference between motor subtypes and provide a 
compelling reason to think that the subtypes are different in ways that link to etiology and 
pathophysiology. PET and SPECT studies indicated that severity of tremor is less related to 
measures of dopaminergic denervation than rigidity and bradykinesia [191]. The two 
subtypes differ on structural MRI parameters indicating that the non-tremor-dominant 
subtype of PD had higher gray matter atrophy in motor, cognitive, limbic and associative 
areas. Further, lower gray matter volumes in the presupplementary motor area and in the 
primary motor area were associated with greater severity of symptoms in patients with 
PIGD [192]. A study of functional connectivity with resting-state MRI raised the question 
on differences in underlying neural circuitry between subtypes showing that the PIGD 
score inversely correlated with subthalamic-putamen connectivity, whereas tremor score 
correlated with subthalamic-cerebellum connectivity [193].  
Further support for the tremor-dominant/PIGD distinction comes from a functional MRI 
study [194] with a grip task in tremor-dominant and nontremor-dominant PD. Reduced 
activation in the prefrontal cortex and globus pallidus of patients with nontremor-
dominant PD was found, suggesting differences in brain activation patterns between the 
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subtypes that extend beyond the occurrence of the tremor itself. 
The etiology of the tremor-dominant/PIGD phenotype distinctions remains obscure, 
however.  
When data-driven cluster analyses are applied and some nonmotor features are included, 
there still often existed a relative prominence of motor features in subtype solutions. 
However, when nonmotor and motor variables are both put into the same statistical 
model, many nonmotor variables are stronger than motor variables in subtype definition 
[167]. 
 
1.3.2 Non-motor dominant subtypes of PD 
As knowledge of non-dopaminergic and nonmotor features has advanced, studies have 
been increasingly incorporating nonmotor variables, with clear improvement in cluster 
quality. Several nonmotor features such as cognitive impairment, sleep disorders, 
autonomic dysfunction, and hallucinations have emerged not only as important 
determinants of subtypes but also as stronger elements than motor variables in subtype 
definition [181]. 
NMS subtype patterns reflect phenotypes driven largely by dominant limbic, brain stem, 
or cognitive involvement, even at a very early motor stage of PD [195]. 
On the other hand, these broad clinical phenotypes reflect the underpinning convergence 
of deficits in multiple transmitter systems and pathways, including the cholinergic, 
                                         C. Pellicano – Neuropsychiatric and Cognitive symptoms in PD 
 
 
 ______ 
  33 
 
noradrenergic, and serotonergic systems that occur in PD [1, 196], [Fig.1.5]. 
 
 
Fig 1.5. Possible routes of spread of pathology in PD as described from pathophysiological studies and consequent 
phenotypic expression and nonmotor subtypes. RBD, rapid eye movement behavior disorder; EDS, excessive daytime 
sleepiness; MCI, mild cognitive impairment. Hatched arrow in cognitive phenotype diagram indicates frontal and parietal 
involvement with underpinning cholinergic dysfunction. Figure adapted from Sauerbier et al. (Sauerbier A, Jenner P, 
Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord 2016;22(Suppl 
1):S41-S46. 
 
A proposal of seven different NMS dominant clinical phenotypes within PD mainly in early 
and untreated phase has been suggested based on clinical observation [196]. These 
observations have been based on three main routes of propagation of the pathology in 
PD. Based on areas of the brain dominantly involved in the pathway of the routes of 
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propagation, various subtypes are proposed. The phenotypic variants proposed are as 
follows [196]:  
 park cognitive (predominantly presents with cognitive impairment at an early 
stage); 
 park apathy (high scores on apathy scales); 
 park depression/anxiety (early manifestation of these symptoms); 
 park sleep (characterized by excessive daytime sleepiness or rapid eye movement 
behavior disorder);  
 park pain (different pain syndromes dominate the clinical picture); 
 park fatigue (exhibited as an independent and severe symptom); 
 park autonomic (gastrointestinal, genitourinary symptom dominant, and 
adrenergic dysfunction dominant). 
Park cognitive and Park apathy are likely related to the neocortical subtype, which shows 
pathology in the neocortex and the presupplementary motor (pre-SMA) in early PD. Park 
sleep and Park autonomic are underpinned by a brainstem spread of pathology in PD, 
while Park pain and Park fatigue are related to the olfactory to limbic route involvement 
[195]. 
However, these subtypes are not universally accepted. 
In data-driven cluster analysis, NMS are often selected as predominant predictors of 
subtype description.  
Erro et al. [197] performed a cluster analysis that incorporates the NMS-Quest and other 
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specific nonmotor specific symptom scales in a cohort of early, untreated patients with 
PD. They described two ‘benign’ clusters, one motor and one combining mild features of 
motor and nonmotor symptoms, and two more rapidly progressive clusters; one motor 
and one predominantly nonmotor. It suggests, as other cluster analyses have, that 
nonmotor symptoms are important defining features of PD subtypes. 
Fereshtehnejad et al [181] recommended a cluster-derived subtyping in which three 
critical nonmotor features (MCI, RBD and orthostatic hypotension) identified the most 
rapidly progressive subtype at baseline. This was termed the diffuse malignant subtype 
[181]. The other two clusters in this study, mainly motor-slow progression and 
intermediate, showed more favorable course of progression, even though the diffuse 
malignant subtype had the same level of motor disability at baseline [181]. This study 
benefitted from a comprehensive list of motor and nonmotor features and longitudinal 
follow-up (>4 years). 
The ONSET PD study [4], a prospective case-control study, analyzed 109 newly diagnosed 
drug-naive PD patients and 107 age- and gender-matched controls. 
The results of cluster analysis identified four different subtypes. A first subtype was 
characterized by RBD-like and constipation cluster characterized by recurrent nightmares, 
dream-enacting behavior, and constipation. Second, a mood cluster characterized by 
anhedonia, apathy, and mood disturbances was identified. Third, a cognition-related 
cluster involving memory and attention problems, fatigue, and excessive daytime 
sleepiness (EDS); and fourth sensory symptom clusters dominated by pain and taste loss 
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were described. No cluster was associated with a specific motor phenotype or severity. 
In a very recent study, Fereshtehnejad et al [198], proposed clinical criteria for subtyping 
PD. They applied a hierarchical cluster analysis on the Parkinson’s Progression Markers 
Initiative (PPMI) dataset consisting of prospective longitudinal clinical characteristics, 
neuroimaging, biospecimen and genetic information of 421 de novo early PD patients. 
They aimed to develop criteria to assign patients to a PD subtype. They identified four 
composite domains: motor (UPDRS-II, UPDRS-III, and PIGD score), cognition (combining all 
available neuropsychological batteries in PPMI), RBD (RBDSQ score), and dysautonomia 
(SCOPA-AUT total score). They identified three clusters of PD subtypes. A “mild-
predominant motor” cluster was characterized by patients with younger age, the mildest 
scores in motor UPDRS, sleep disorders, olfactory and autonomic dysfunction and the 
least affected cognitive performance in almost all domains at baseline. By contrast, the 
“diffuse malignant” cluster included patients with the worst scores in both motor and non-
motor components (except for olfactory dysfunction and hallucinations). An 
“intermediate cluster” described an intermediate status in most motor and nonmotor 
manifestations at baseline. Interestingly, the authors were able to demonstrate that, 
despite similar disease duration, subtypes differed substantially in terms of neuroimaging, 
CSF biomarkers, clinical characteristics and disease progression over time. Indeed, 
patients with the diffuse malignant subtype have more prominent dopaminergic deficit 
on SPECT, more atrophy in PD-specific brain networks on MRI, a more Alzheimer’s disease-
like CSF profile and progress more rapidly on motor and cognitive performance [198]. 
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NMS subtyping is an important step forward in the translation of pathophysiological 
advances in PD to clinical practice. Indeed, NMS subtyping would enrich the design of 
clinical trials and recruitment of patients as well improves the knowledge about the 
natural history of PD. 
 
1.4 Unmet Needs and future directions 
Such a broad clinical and pathophysiological heterogeneity poses a challenge to the 
clinicians and researchers. In particular, NMS represent “a challenge within a challenge” 
because they continue to be a key determinant of patients’ and careers’ quality of life at 
huge societal costs. NPS and cognitive symptoms contribute heavily to the burden of PD 
since the very early stage of the disease. 
Further, the occurrence of NPS in PD patients may frequently be related to potentially 
additive mechanisms, including psychological reactions to disability, psychiatric symptoms 
caused by structural brain damage, and adverse effects of DRT. Indeed, knowledge is still 
limited about structural brain areas and the neuropathological and pathophysiological 
changes that may associate with NPS in PD. The main limitation of investigating these 
symptoms is that NPS are influenced by DRT and often are hardly differentiated from each 
other because of symptom overlaps. 
The research in the field urges to fulfill crucial unmet needs, as highlighted also by the 
National Institute of Neurological Disorders and Stroke PD 2014 conference [168]: 
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 Extensive insight into untreated PD patients, who offer a suitable model to study 
the expression of NMS in comparison to motor symptoms and might also provide 
an unbiased framework to generate pathophysiological hypotheses able to explain 
the complex heterogeneity of PD. 
 Major advances in understanding the diversity of NMS, their evolution in the 
diverse disease stages (untreated, early and advanced PD patients), and their 
differential effects on quality of life, as well as their possible progression pattern 
and their possible contribution in differential diagnosis with other degenerative 
parkinsonism. 
 Identification of robust and replicable non-motor subtypes with the potential for 
prognostic indicators and specific treatments. Indeed, identifying different 
subtypes of PD is the mainstay for better understanding underlying disease 
mechanisms, predicting prognosis, and ultimately developing personalized 
management strategies. 
 Collection of robust evidence for treatment of non-motor symptoms in PD. 
 Implementations of technologies such as “body-worn” or “smart home” 
technologies that provide more detailed characterization of an individual’s motor, 
cognitive, and behavioral impairments for use in populations and settings. 
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 Identification of possible biomarkers suitable for defining the premotor stages of 
PD as well as the clinical patterns of PD into specific endophenotypes with a 
particular attention to biofluid biomarkers and biopsy of peripheral tissue that 
accumulates LBs (i.e., gut, salivary glands, and skin). 
 Establishment of an integrated network of health-care specialist comprising PD 
nurse specialist, speech and language therapist, physiotherapist, occupational 
therapist, clinical psychologist and neuropsychiatrist in order to deal with the 
variegate symptoms occurring in PD such as dribbling of saliva, pain, sexual 
dysfunction, impulse control disorders and cognitive impairment. 
 
Greater awareness of non-motor PD symptoms and successful answers to such a broad 
unmet needs have important practical implications for people with a chronic condition 
like PD. In particular, knowing the specific variability of each PD patient at baseline allows 
one to estimate prognosis and the spectrum of clinical manifestations that are likely to 
appear. This can be used to plan treatment protocol, avoid medications with high chance 
of side effects, guide clinicians as to what monitoring should be emphasized in specific 
patients and therefore more accurately counsel patients and families. Future clinical trials 
might also aim at investigating the effects of interventions on each PD subtype through 
subgroup analysis, to provide evidence for a tailored and more efficiently personalized 
treatment approach. 
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2. Research Plan 
The above-described scenario depicts several strands of research in the field of NMS of PD 
with specific emphasis on NPS and cognitive symptoms. The several unmet needs 
identified so far throw down the gauntlet to each researcher and clinician. The 
overarching aim of the work carried out during the Academic Years 2014-2017 was, 
therefore, to investigate the nature and relevance of NPS and cognitive symptoms in the 
diverse disease stages. To this end, their contribution in the characterization of different 
clinical phenotypes, in differential diagnosis, in disease complication, and their correlation 
with MRI findings have been evaluated in different scenario of untreated, early and 
advanced PD patients.  
Given these premises, a research plan has been developed, the results of which will be 
discussed in the present dissertation: 
 NPS and cognitive symptoms in untreated PD patients: 
o Identification of neuropsychiatric and cognitive symptoms differences 
according to the body side of onset of parkinsonism in unmedicated PD 
patients. 
o Identification of neuropsychiatric and cognitive symptoms differences 
according to the dominant motor subtype in unmedicated PD patients. 
 NPS and cognitive symptoms in early PD patients: 
o The contribution of neuropsychiatric and cognitive symptoms in 
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differential diagnosis among PD and the major subtypes of PSP, the second 
more common degenerative parkinsonism. 
o Identification of affective impairment and emotional tone differences 
among PD and the major subtypes of PSP. 
 NPS and cognitive symptoms in advanced PD patients: 
o Neuropsychiatric and cognitive characteristics of pathological gambling 
and not-otherwise-specified ICDs in PD patients 
o Investigation in MRI of morphometric correlates of ICDs in PD patients. 
o The contribution of NPS and cognitive symptoms in affecting the 
compliance to undergo MRI scan in PD patients 
Finally, as overviewed in the “Ancillary Research” section, a parallel effort was made in 
identifying possible biomarkers on peripheral tissue (i.e., salivary glands) and, under the 
umbrella of two European Projects, in validation of NMS home monitoring tools and in 
defining an integrate platform based on dynamic and personalized orchestration of care 
services for PD patients. 
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3. General methodology: neuropsychiatric and cognitive batteries  
Several neuropsychiatric and cognitive tests were applied in the research. 
In this section, an overview of more commonly used tests and scales is given. In the 
following chapters, only the name/abbreviation of the tests and scales is specified. 
 
3.1 Neuropsychiatric assessment  
 The Beck Depression Inventory (BDI) [1]: 21-item self-report inventory. The total 
score is the sum of the individual item scores. We also calculated the psychic 
subscore and the somatic subscore by combining the first 14 items and the 
remaining 7 items, respectively.  
 The Hamilton Depression Rating Scale (HDRS) [2]: 17-items scale for quantification 
of severity of depressive symptoms. The psychic subscore and the somatic 
subscore are also calculable. 
 The Hamilton Anxiety Rating Scale (HARS) [3]: 14-items scale for quantification of 
severity of anxious symptoms. 
 The 20-item Toronto Alexithymia Scale (TAS-20) [4, 5]: self- report instrument for 
the measurement of alexithymic characteristics. It comprises three subscales that 
assess distinct facets of alexithymia: F1, difficulty identifying feelings; F2, difficulty 
describing feelings; F3, an externally oriented analytic mode of thinking. To 
evaluate the prevalence of alexithymia, patients with a TAS-20 score greater than 
60 were considered alexithymic, whereas patients ranging from 52 to 60 were 
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considered as borderline alexithymic and those scoring less than 52 were 
considered non alexithymic. 
 The Snaith–Hamilton Pleasure Scale (SHAPS) [6]: 14 items self-rated instrument, 
used to evaluate hedonic tone. The subject is requested to agree or disagree with 
a statement in each item (definitely agree, agree, dis-agree, and definitely 
disagree). The four available answers are divided into dichotomous categories 
(agree=0; disagree=1), ranging from 0 to 14 and with a cut-off score of 2 as the 
best discrimination between “normal” (a score of 2 or less was categorized as 
hedonic) and “abnormal” (a score above 2 was categorized as anhedonic) level of 
hedonic tone.  
 The Apathy Rating Scale (ARS) [7]: to assess apathetic symptom severity. 
 The Parkinson's Psychosis Rating Scale (PPRS) [8]: to assess the severity of psychotic 
symptoms. 
 The Structured Clinical Interview for DSM-IV TR (SCID-P) [9]: a structured 
psychiatric interview for the identification of psychiatric disorders according to the 
DSM-IV-TR criteria. 
 
3.2 Cognitive assessment 
 The Mini Mental State Examination (MMSE) [10]: a global index of cognitive 
impairment with the score ranging from 30 (no impairment) to 0 (maximum 
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impairment). 
 The Rey’s 15-word test – Immediate Recall (RIR) and Delayed Recall (RDR) [11]: to 
evaluate short- and long-term verbal memory, with total scores given by the total 
number of words recalled in each test. 
 The Phonologic (PVF) and Semantic (SVF) Verbal Fluency tests [12]:  to assess 
language ability: in which the total score is the total number of words produced 
during each test. 
 The Copy of the Rey-Osterrieth picture (CRO) and Delayed Recall of the Rey-
Osterrieth picture (DRO) [13]: to evaluate complex constructional praxis and long-
term visual memory, with scores ranging from 0 (maximum impairment) to 36 (no 
impairment) on both tests. 
 The Wisconsin Card Sorting Test – short form (WCST-SF) [14]: to explore executive 
functions. WCST-SF requires matching 48 cards to four key cards by color, shape, 
and number and choosing the six correct categories from feedback given by the 
examiner. 
 Stroop Word-Color Test (SWCT) [15]: to assess frontal abilities of simple attention, 
attention shifting and control, which consists of three subtest: “word reading”, 
“color naming” and “interference time”. 
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4. Untreated PD patients 
4.1 Neuropsychiatric and cognitive symptoms and body side of onset of parkinsonism in 
unmedicated Parkinson's disease patients 
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at: 
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4.1.1 Background 
Unilateral onset and asymmetric progression of motor symptoms are key clinical features 
of idiopathic PD [1]. 
Given the lateralization of several cognitive and affective functions in the cerebral 
hemispheres and the possible role of impaired dopaminergic transmission on non-motor 
symptoms in PD, the question raises whether body side of onset of parkinsonian motor 
symptoms might influence cognitive and/or neuropsychiatric domains in the early stages 
of PD. Indeed, a recent review of the published studies [2] concluded that PD patients with 
right-side motor symptom predominance (RPD) preferentially show difficulties in language 
and verbal memory, whereas those with left-side motor symptom predominance (LPD) 
have greater problems with tasks of spatial attention, visual-spatial orienting and memory, 
and mental imagery. More recently, however, Poletti et al. reported that the side of motor 
predominance scarcely influences cognition in the early, untreated stage of PD [3].  
To further clarify the issue, in the present study we investigated the prevalence and 
severity of neuropsychiatric and cognitive alterations in a cohort of drug-naïve PD patients, 
divided into two groups according to the body side of onset of motor symptoms. We 
hypothesized the lack of relationships between motor lateralization and non-motor 
domains examined. 
  
4.1.2 Methods 
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The study was carried out on 84 subjects diagnosed with PD according to the international 
guidelines [4], and 84 age-, sex- and educational level-matched healthy subjects (HC). PD 
patients were recruited during scheduled visits at the Outpatient Services for Movement 
Disorders of our Institutions. HC were recruited in the same geographical area. The study 
protocol was approved by the Ethical Committee of the “Fondazione Santa Lucia, IRCCS” 
and each subject signed an informed consent before enrollment. All subjects were right-
handed and had vision and hearing sufficient for compliance with testing procedures. PD 
patients were all drug naïve of antiparkinsonian drugs. Six of PD patients were under 
therapy with antidepressant, 12 with benzodiazepine, none with antipsychotic drugs 
(Table 4.1). 
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Table 4.1: Demographic and Clinical Features of the Subjects Enrolled 
 
RPD (n=42) 
Mean ± SD 
LPD (n=42) 
Mean ± SD 
HC (n=84) 
Mean ± SD 
F df P 
Age (Years) 63.6±8 63±10.7 63.1±10.1 0.062 2 0.939 
Education (Years) 11.4±4.7 11.5±4.7 11.9±3.9 0.165 2 0.848 
Age at onset (Years) 62,4±8.2 61.8±10.7 Na - 82 0.740 
Disease duration (Years) 0.9±0.9 1.1±0.8 Na  82 0.451 
H&Y score 1.6±0.5 1.5±0.5 Na - 82 0.312 
UPDRS-III score 15.1±8.9 15.1±8.3 Na - 82 0.979 
 n  n  n  χ2  P 
Sex (F/M) 16/26 16/26 32/52 0.000 2 1 
Minor depression (%) 13 (32%) 17 (39%) 7 (8%) 20.243 4 0.001* 
Anxiety (%) 15 (35.7%) 16 (38%) 0 (0%) 0.051 1 0.821 
Antidepressant drugs (%) 3 (7.1%) 3 (7.1%) 0 (0%) 0.000 1 1 
Benzodiazepine (%) 5 (12%) 7 (16.7%) 0 (0%) 0.389 1 0.533 
Antipsychotic drugs (%) 0 (0%) 0 (0%) 0 (0%) - - - 
SD=standard deviation; df=degrees of freedom; na=not applicable; H&Y=Hoehn and Yahr scale; UPDRS-III= Unified 
Parkinson's Disease Rating Scale – part III; *Statistically significant differences. 
 
Common exclusion criteria for all subjects enrolled were:  
1) major not stabilized medical illnesses;  
2) known or suspected history of alcoholism, drug dependence or abuse, other 
neurological disorders, head trauma and mental disorders (apart from mood or anxiety 
disorders) according to the Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition Text Revision (DSM-IV-TR);  
3) Mini Mental State Examination (MMSE) score <26;  
4) diagnosis of dementia according to the Movement Disorder Society clinical diagnostic 
criteria [5];  
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5) presence of vascular brain lesions, neoplasms and/or marked cortical and subcortical 
atrophy at CT and/or MRI scan. 
PD patients were divided into 2 groups (42 LPD and 42 RPD) according to the body side of 
onset of motor symptoms. This was accomplished combining history data with the UPDRS 
part III scores in terms of laterality. At the time of assessment, in all patients parkinsonism 
predominated at the site of onset. 
Neurological and Psychiatric Examinations 
Demographic and neurological features were collected by trained neurologists at 
enrollment. Disease stage was measured by the modified H&Y scale, and the severity of 
motor symptoms by the UPDRS-III scale.  
Within one week from enrollment, each subject was submitted to the SCID-P. Psychiatric 
diagnoses were made by a senior psychiatrist. In all PD patients, dopaminergic therapy was 
started following completion of the study protocol and carried out for at least 18 months 
to confirm the positive response to dopaminergic drugs. 
Neuropsychiatric and Neuropsychological Evaluations  
All participants underwent the following neuropsychiatric scales: HARS, HADRS, BDI (total, 
somatic- and psychic-subscores) and ARS.  
The neuropsychological examination included: MMSE, RIR, RDR, PVF, SVF, CRO, DRO, 
WCST-SF and SWCT. 
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Psychopathologic and neuropsychological evaluations were performed by 2 trained 
neuropsychologists (FA and RL) who were blind to the study groups. Acceptable inter-rater 
reliability was defined as k>0.80.  
Statistical Analysis 
All analyses were performed using SPSS Statistics v22.0. Differences among the 3 groups 
were assessed by the chi-squared test for categorical variables and by a series of analyses 
of variance (ANOVAs) for continuous variables (i.e, demographic, neuropsychiatric and 
neuropsychological). Post-hoc comparisons were performed using Fisher's test for 
variables showing statistically significant differences on ANOVAs. A Student’s t-test was 
performed for direct comparison of values measured for each variable between LPD and 
RPD patients. Further, we have compared the percentage of LPD and RPD patients varying 
1.5 standard deviation (SD) from HC scores using the chi-squared test. For all tests, the 
level of significance was set at p<0.05. 
 
4.1.3 Results 
As shown in Table 4.1, there was no significant difference in any demographic feature 
among three groups. Moreover, there were no differences between RPD and LPD as to age 
at onset, disease duration or motor disability (Table 4.1). 
Significantly higher prevalence of depression and anxiety and severity of neuropsychiatric 
impairment were observed in both LPD and RPD as compared to HC (Tables 4.1 and 4.2a). 
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There were no differences between LPD and RPD patients as to the prevalence or severity 
of neuropsychiatric disorders (Tables 4.1 and 4.2a). We have observed a trend towards 
significance at the BDI psychic, LPD subjects showing higher scores (Table 4.2a). Both RPD 
and LPD scored worse than HC at all neuropsychological tests except DRO, SWCT 
interference and WCST-SF categories scores (Table 4.2a). Again, there was no significant 
difference between LPD and RPD patients on any neuropsychological variables 
investigated (Table 4.2a).  
In an ancillary analysis, we have calculated the percentage of LPD and RPD patients varying 
1.5 SD from HC scores (Table 4.2b). These results revealed that higher percentage of LPD 
patients than RPD ones deviate from HC scores at HDRS, BDI total and BDI psychic. 
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Table 4.2a: Neuropsychological and Neuropsychiatric Scores 
 
RPD 
(n=42) 
Mean±SD 
 
LPD 
(n=42) 
Mean±SD 
HC 
(n=84) 
Mean±SD 
F df P 
Post Hoc analysis 
P 
RPD vs. 
HC 
P 
LPD vs. 
HC 
P 
RPD 
vs. 
LPD 
MMSE 28.4±2.1 28.7±1.8 29.1±1.3 2.350 2 0.0985 / / / 
RIR 37.7±11.1 38.7±12.1 43.9±8.8 6.467 2 0.002* 0.0018* 0.0086* 0.658 
RDR 7.6±3.8 8.4±3.8 9.5±2.8 4.548 2 0.0119* 0.0042* 0.0857 0.309 
CRO 29.5±6 29.7±4.6 32±2.9 6.634 2 0.0017* 0.002* 0.005* 0.819 
DRO 16.3±6.2 15.4±6.7 17.2±5.9 1.215 2 0.299 / / / 
SWCT 
interference 
43.8±19.2 41.8±13 39.1±12 1.557 2 0.213 / / / 
SWCT word 16±5.8 15.9±5.2 13.9±3.4 4.267 2 0.0156* 0.0152* 0.0219* 0.905 
SWCT color 22.1±7.6 20.6±5.6 16.2±4.3 3.725 2 0.0262* 0.0076* 0.207 0.215 
SVF 19.3±6.3 19.7±5.4 22±5.5 4.361 2 0.0143* 0.0103* 0.0295* 0.730 
PVF 31.1±11.8 32.1±12.1 37.1±11.1 4.880 2 0.0087* 0.0064* 0.022* 0.692 
WCST-SF 
categories 
5.4±1.4 5.5±1 5.8±0.6 2.544 2 0.0817 / / / 
WCST-SF 
perseverative 
errors 
2.5±4.0 2.5±3.2 1.1±2.5 4.292 2 0.0152* 0.0170* 0.0189* 0.972 
WCST-SF non-
perseverative 
errors 
2.5±3.1 2.5±2.7 1.1±1.7 7.169 2 0.0010* 0.0023* 0.0023* 1 
HARS 7.4±4.6 8.6±4.8 4.7±4 12.595 2 <0.0001* 0.0014* <0.0001* 0.216 
HDRS 7.4±4 8.5±4.5 3.5±3.7 26.024 2 <0.0001* <0.0001* <0.0001* 0.200 
BDI total  7.5±.4.4 9.2±6.3 5.4±4.9 8.119 2 0.0004* 0.0287* 0.0001* 0.141 
BDI somatic 3.4±2.3 3.8±2.7 2.2±1.9 8.677 2 0.0003* 0.0031* 0.0003* 0.532 
BDI psychic 4.1±2.9 5.4±4.1 3.2±3.6 5.418 2 0.0053* 0.2014 0.0012* 0.0847 
ARS 7±5 7.8±6.3 5.02±5.6 3.883 2 0.0225* 0.0647 0.0109* 0.535 
SD=standard deviation; df=degrees of freedom; MMSE=Mini Mental State Examination; RIR=Rey’s 15-word test – 
Immediate Recall; RDR=Rey’s 15-word test – Delayed Recall; CRO=Copy of the Rey-Osterrieth picture; DRO=Delayed 
Recall of the Rey-Osterrieth picture; SWCT=Stroop Word-Color Test; SVF=Semantic Verbal Fluency; PVF=Phonologic 
Verbal Fluency; WCST-SF=Wisconsin Card Sorting Test – short form; HARS=Hamilton Anxiety Rating Scale; 
HDRS=Hamilton Depression Rating; Scale; BDI= Beck Depression Inventory; ARS=Apathy rating scale. 
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Table 4.2b: Neuropsychological and Neuropsychiatric Score 
a % of patients with score ≤ 1.5 SD than HC group; b % of patients with score ≥ 1.5 SD than HC group; *Statistically 
significant differences. 
 
4.1.4 Discussion 
Neuropathologic [6], neuroimaging [7] and clinico-pharmacologic [8] data suggest that 
dopamine depletion may influence neuropsychiatric and cognitive symptoms in the early 
 
RPD (n=42) 
Mean±SD 
LPD (n=42) 
Mean±SD 
HC (n=84) 
Mean±SD 
χ2 df P 
RIR (%)a 12 (28.6%) 13 (30.9%) / 0.057 1 0.811 
RDR (%)a 14 (33.3%) 11 (26.2%) / 0.513 1 0.474 
CRO (%)a 9 (21.4%) 10 (23.8%) / 0.068 1 0.794 
DRO (%)a 4 (9.5%) 5 (11.9%) / 0.124 1 0.724 
SWCT interference (%)b 9 (21.4%) 7 (16.7%) / 0.309 1 0.578 
SWCT word (%)b 9 (21.4%) 7 (16.7%) / 0.309 1 0.578 
SWCT color (%)b 17 (40.5%) 13 (31%) / 0.83 1 0.362 
SVF (%)a 8 (19.1%) 7 (16.7%) / 0.081 1 0.776 
PVF (%)a 11 (26.2%) 9 (21.4%) / 0.263 1 0.608 
WCST-SF categories (%)a 7 (16.7%) 5 (11.9%) / 0.389 1 0.533 
WCST-SF perseverative 
errors (%)b 
10 (23.8%) 9 (21.4%) / 0.068 1 0.794 
WCST-SF non-
perseverative errors (%)b 
9 (21.4%) 11 (26.2%) / 0.263 1 0.608 
HDRS (%)b 7 (16.7%) 16 (38%) / 4.850 1 0.0277* 
HARS (%)b 9 (30.9%) 13 (21.4%) / 0.985 1 0.321 
BDI total (%)b 4 (9.5%) 13 (31%) / 5.974 1 0.0145* 
BDI somatic (%)b 6 (14.3%) 11 (26.2%) / 1.844 1 0.174 
BDI psychic (%)b 4 (9.5%) 11 (26.2%) / 3.977 1 0.0461* 
ARS (%)b 5 (11.7%) 7 (16.7%) / 0.389 1 0.533 
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stages of PD. The present results demonstrate, however, that body side of onset of motor 
symptoms does not significantly affect the pattern and severity of neuropsychiatric and 
neuropsychological alterations in early, unmedicated, PD patients. To our knowledge, this 
is the first study investigating systematically similarities and differences of both 
neuropsychiatric and cognitive features in unmedicated LPD vs. RPD patients by the use 
of rigorous psychiatric diagnostic criteria associated with specific psychopathologic and 
neuropsychological scales. Our results, therefore, strongly support the uncoupling 
between motor and non-motor (neuropsychiatric/cognitive) consequences of damage of 
dopaminergic nigrostriatal neurons in the early stages of PD. A trend was observed at the 
BDI psychic, LPD patients showing higher scores than RPD. Moreover, higher number of 
LPD patients as compared to RPD ones deviated from HC at depression scales. This 
suggests that LPD patients may suffer from slightly stronger severity of depressive 
symptoms unrelated to the degree of motor impairment. This slight difference between 
LPD and RPD patients is in line with the role of the right hemisphere in processing negative 
emotions, pessimistic thoughts and unconstructive thinking styles. 
Our findings showing the significant impairment of several cognitive domains (verbal 
memory, language, complex constructional praxis, attention and executive functions) in 
drug naïve PD patients further confirm the presence of slight, although significant, 
cognitive symptoms in newly diagnosed, drug-naïve PD patients. 
The lack of difference in cognitive performances between LPD and RPD patients reported 
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here is in contrast with previous reports showing the preferential impairment of linguistic 
and verbal memory functions in RPD and visual-spatial functions in LPD [review in 2]. In 
this respect, it is noteworthy that the majority of studies reviewed previously [2] were 
carried out on medicated PD patients, and in several instances, subjects in more advanced 
disease stage were also included. Indeed, one cannot exclude that cognitive differences 
between LPD or RPD patients may emerge in more advanced disease stages, particularly 
after development of axial motor symptoms.  
In conclusion, the results of this study clearly show that body side of onset of motor 
symptoms does not influence the pattern or severity of neuropsychiatric and cognitive 
abnormalities in unmedicated PD patients. These findings support the hypothesis of 
uncoupling between motor and non-motor consequences of dopamine depletion in early, 
unmedicated, PD, and suggest that differences reported in previous reports may be 
secondary to interactions between disease progression and therapeutic management. 
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4.2 Cognitive and neuropsychiatric profile of tremor dominant and akinetic-rigid motor 
subtypes of newly diagnosed drug naïve Parkinson’s disease patients 
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4.2.1 Background 
PD is a heterogeneous neurodegenerative disorder characterized by motor and non-
motor symptoms. In consideration of the predominant motor features, it is possible to 
distinguish two main different clinical subtypes: tremor dominant (TD) and akinetic-rigid 
(ART). Moreover, a mixed phenotype (MIX), not presenting one prevailing motor feature 
could be identified [9, 10]. 
It has been suggested that the two motor presentations of PD, ART and TD, are 
characterized by a different risk and severity of specific non-motor symptoms along the 
disease course such as depression, apathy and cognitive problems [11,12]. In particular, 
ART subjects show a more rapid clinical progression and have an increased risk to develop 
disability and dementia [11]. On the other hand, it has been showed that the TD variant 
has a slower disease progression, less cognitive decline, and lower incidence of 
neuropsychiatric complications such as visual hallucinations and depression [13], when 
compared to the ART group [14-17]. These different features of the two PD motor patterns 
are supported by pathophysiological investigations, showing a more widespread 
reduction of pallidal and striatal dopamine levels in ART patients, when compared to TD 
ones [13].  
According to our knowledge, studies conducted on newly diagnosed drug naïve PD 
patients, with the aim of investigating cognitive and behavioral differences between ART 
and TD motor subtypes in the early stage of the disease are rare and need to be explored 
further. In particular, it has been demonstrated that de novo drug naive patients with 
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postural instability/gait difficulty (PIGD) PD motor type showed significantly higher 
alexithymic features compared to patients of other motor types (TD and MIX) [18] and 
that PIGD PD presented a higher frequency of MCI respect to TD patients. However, the 
comparison between cognitive performances of TD and PIGD patients showed that the 
former outperformed the latter only in the Boston Naming Test Short Form, a test to 
assess language ability [19]. In line with this, Domellof and colleagues did not find 
significant differences in the neuropsychological variables between the PIGD and the TD 
phenotype patients [20].  
Investigating PD motor subtypes in the early stage of the disease may provide more insight 
into the progression of non-motor symptoms, in particular on cognitive and psychological 
symptoms evolution, in order to stratify the individual prognostic risk and offer a more 
precise disease evolution tailored on patient subgroup. 
Thus, we sought to explore in detail neuropsychological and neuropsychiatric 
characteristics in the very early stage of the three motor subtypes of PD (akinetic-rigid, 
tremor-dominant and mixed). We studied newly diagnosed drug naïve patients in order 
to avoid the possibility that confounding factors, such as disease duration or drug 
treatment, might variably affect the cognitive, psychopathological and motor results. 
 
4.2.2 Methods 
Participants 
The study was carried out on 68 consecutive newly diagnosed drug naïve PD patients 
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diagnosed according to international guidelines (Hughes, Daniel et al. 1992). Clinical 
diagnoses of PD were confirmed on 12 and 24 months follow-up evaluations from 
symptom onset. All patients were recruited at outpatient services for movement disorders 
of four institutions (I.R.C.C.S. Santa Lucia Foundation, Neurological Unit of “San Giovanni 
Addolorata” Hospital, NESMOS Department of “Sapienza” University, Movement Disorder 
Unit of “Sant’Andrea” Hospital, and Department of Medicine of Systems of University “Tor 
Vergata”, Rome, Italy). Based on different motor presentations of PD, patients were 
divided in three subgroups according to Kang et al. guidelines [1]: ART (n=39), TD (n=22) 
and MIX (n=7). Subtypes were defined according to the ratio of patient’s UPDRS III tremor 
score (obtained as sum of Items 20 and 21 divided by 4) to her/his mean UPDRS 
akinetic/rigid score (sum of items 22–27 and 31 divided by 15) such that (1) a ratio = 1.0 
equals tremor-dominant, (2) a ratio = 0.80 equals akinetic–rigid, and (3) a ratio between 
0.80 and 1.0 equals mixed [1]. 
Age at symptom onset was defined as the first appearance of motor symptoms according 
to the patient. Duration of the disease was defined as the time between symptom onset 
and time of diagnosis. 
Inclusion criteria were the following:  
1) patients at the first diagnosis of PD, not yet undergoing antiparkinsonian therapy;  
2) vision and hearing sufficient for compliance with testing procedures;  
3) MMSE score ≥ 26;  
4) no dementia according to the Movement Disorder Society (MDS) clinical diagnostic 
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criteria [5]. 
Exclusion criteria were: 
1) presence of major non stabilized medical illnesses (i.e. diabetes, obstructive pulmonary 
disease or asthma, hematologic/oncologic disorders, vitamin B12 or folate deficiency, 
pernicious anemia, clinically significant and unstable active gastrointestinal, renal, 
hepatic, endocrine or cardiovascular disorders);  
2) known or suspected history of alcoholism, drug dependence and abuse, head trauma 
and mental disorders (apart from mood or anxiety disorders) according to the Diagnostic 
and Statistical Manual of Mental Disorders, Fifth Edition [21];  
3) presence of vascular brain lesions, brain tumor and/or marked cortical and subcortical 
atrophy on CT and/or MRI scan. 
The study was approved by the Ethical Committee of I.R.C.C.S. Santa Lucia Foundation 
and, in accordance with the Helsinki Declaration, each subject signed an informed consent 
form prior to enrolment. 
Neurological and Psychiatric Examinations  
Sociodemographic data were collected by neurologists during the clinical examination. 
Clinical characteristics, such as age at onset of first motor symptoms and duration of illness 
were also recorded. The evaluation of motor symptoms was made using the UPDRS-III [22] 
and disease stage was measured by the modified H&Y scale [23]. 
All patients underwent a Structured Clinical Interview for DSM-5 Disorders- Clinician 
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Version (SCID-5-CV) [24] for the identification of psychiatric disorders according to the 
DSM-V criteria (American Psychiatric Association [21].  
Psychiatric diagnoses were made by a senior psychiatrist. 
The day after completion of the baseline evaluation, all patients started antiparkinsonian 
treatment according to the guidelines of European Federation of Neurological Societies 
and MDS-European Section [25].  
Neuropsychiatric and Neuropsychological assessment  
All participants underwent the following neuropsychiatric scales: HDRS, HRS, TAS-20, 
SHAPS and ARS. Anhedonia diagnosis was based on a SHAPS cut-off score of > 2, and 
apathy diagnosis on Starkstein [26] criteria adapted from Marin [27]. 
All patients were submitted to a detailed neuropsychological evaluation including: MMSE, 
RIR, RDR, PVF, SVF, CRO, DRO, WCST-SF and SWCT. 
All testing and clinical evaluations were carried out from trained specialists who were blind 
to the aims of the study. Acceptable inter-rater reliability was defined as k>0.80. 
Statistical analysis 
The distribution of the analysed factors was verified by using the Shapiro-Wilk test. 
Between group comparisons for sociodemographic, neurological, neuropsychiatric and 
neuropsychological variables were performed using ANOVA as well as, in the case of 
distribution that was different than normal, using Kruskal-Wallis ANOVA for continuous 
variables and χ2 tests for categorical variables, followed by Fisher’s Protected Least 
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Significant Difference (PLSD) test post-hoc comparisons when appropriate. 
The level of statistical significance was defined as p level less than 0.05. 
 
4.2.3 Results 
Table 4.2.1 shows the sociodemographic and clinical characteristics of the study 
populations. ART, TD and MIX PD subgroups did not differ significantly in any of these 
variables.  
There were no significant differences in neuropsychiatric scores (Table 4.2.2) among ART, 
TD and MIX PD patients. 
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Table 4.2.1. Sociodemographic and neurological characteristics of ART, TR and MIX PD patients.  
Characteristics 
ART (n=39) 
Mean (SD) 
TD (n=22) 
Mean (SD) 
MIX (n=7) 
Mean (SD) 
F df p 
Age (years)  63.7 (9.8) 63.4 (9.8) 64.7 (12.5) 0.045 2 0.956 
Age at symptom onset (years) 63.0 (9.8) 62.8 (9.7) 64.0 (12.5) 0.040 2 0.961 
Duration of illness (years) 0.7 (0.5) 0.6 (0.6) 0.7 (0.5) 0.058 2 0.943 
Education (years) 11.4 (4.8) 12.1 (3.7) 15.0 (2.2) 2.119 2 0.128 
UPDRS-III 13.3 (8.0) 12.9 (8.1) 18.3 (10.2) 1.246 2 0.294 
H&Y  1.5 (0.5) 1.4 (0.5) 1.8 (0.6) 1.852 2 0.232 
 n (%)  n (%) n (%) χ2  p 
Gender (male) 29 (74.4) 12 (54.5) 3 (42.9) 4.049 2 0.132 
PD=Parkinson’s disease; ART=akinetic-rigid PD subtype; TD=tremor-dominant PD subtype; MIX=mixed PD subtype; 
SD=standard deviation; df=degrees of freedom; UPDRS-III=Unified Parkinson’s Disease Rating Scale–Part III; H&Y=Hoehn 
and Yahr scale.  
 
 
Table 4.2.2. Neuropsychiatric scores of ART, TR and MIX PD patients. 
Variables 
ART (n=39) 
Mean (SD) 
TD ( n=22) 
Mean (SD) 
MIX (n=7) 
Mean (SD) 
F df p 
HDRS 7.2 (3.8) 7.2 (3.7) 9 (3.3) 0.823 2 0.444 
HARS 6.8 (3.3) 7.4 (4.8) 10.0 (5.1) 1.919 2 0.155 
SHAPS 0.2 (0.5) 0.2 (0.4) 0.0 (0.0) 0.850 2 0.432 
ARS  6.7 (5.0) 6.7 (4.2) 10.3 (2.6) 3.971 2 0.165 
TAS-20 total  44.7 (12.5) 43.9 (9.5) 46.3 (12.8) 0.108 2 0.897 
TAS-20 F1 11.5 (5.6) 12.2 (5.8) 13.6 (6.1) 0.412 2 0.664 
TAS-20 F2 13.0 (6.2) 12.9 (5.1) 12.1 (4.2) 0.065 2 0.937 
TAS-20 F3 20.2 (5.6) 18.8 (5.6) 20.6 (4.9) 0.525 2 0.594 
PD=Parkinson’s disease; ART=akinetic-rigid PD subtype; TD=tremor-dominant PD subtype; MIX=mixed PD subtype; SD=standard 
deviation; df=degrees of freedom; HDRS=Hamilton Depression Rating Scale; HARS=Hamilton Anxiety Rating Scale; SHAPS=Snaith-
Hamilton Rating Scale; ARS=Apathy Rating Scale; TAS-20=Toronto Alexithymia Scale-20 item; TAS-20 F1=TAS-20 difficulty identifying 
feelings; TAS-20 F2=TAS-20 difficulty describing feelings; TAS-20 F3=TAS-20 externally oriented thinking.  
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The three groups of PD patients did not significantly differ in neuropsychological scores 
(Table 4.2.3). 
 
Table 4.2.3. Neuropsychological scores of ART, TR and MIX PD patients. 
Variables 
ART (n=39) 
Mean (SD) 
TD (n=22) 
Mean (SD) 
MIX (n=7) 
Mean (SD) 
F df p 
MMSE 28.5 (2.0) 28.9 (1.4) 29.4(1.1) 0.986 2 0.379 
RIR 38.3 (11.1) 40.9 (12.4) 37.6 (8.3) 0.420 2 0.658 
RDR 7.9 (3.7) 8.8 (4.0) 7.4 (2.7) 0.599 2 0.552 
CRO 29.1 (6.1) 30.0 (5.4) 31.4 (3.6) 0.578 2 0.564 
DRO 16.2 (6.5) 17.1 (7.1) 13.1(6.6) 0.978 2 0.382 
SWCT-word reading (sec) 15.8 (5.4) 14.4 (2.8) 14.7 (2.9) 0.705 2 0.498 
SWCT-color naming (sec) 21.4 (8.1) 19.6 (4.4) 20.7 (4.0) 0.491 2 0.614 
SWCT-interference time (sec) 42.0 (13.0) 38.5 (11.8) 38.6 (14.2) 0.620 2 0.541 
WCST-SF categories 5.4 (1.3) 5.5 (1.1) 6.0 (0.0) 0.717 2 0.492 
WCST-SF Perseverative errors 2.7 (3.7) 2.5 (4.4) 1.4 (0.8) 0.347 2 0.708 
WCST-SF Non perseverative errors 3.0 (2.9) 2.0 (2.8) 1.6 (1.1) 1.245 2 0.295 
PVF 30.7 (11.7) 36.3 (10.8) 34.6 (11.1) 1.780 2 0.177 
SVF 20.1 (5.1) 21.5 (5.1) 21.1 (4.8) 0.546 2 0.582 
PD=Parkinson’s disease; ART=akinetic-rigid PD subtype; TD=tremor-dominant PD subtype; MIX=mixed PD subtype; 
SD=standard deviation; df=degrees of freedom; RIR=Rey’s 15-word test - Immediate Recall; RDR=Rey’s 15-word test - 
Delayed Recall; CRO=Copy of the Rey-Osterrieth picture; DRO=Delayed Recall of the Rey-Osterrieth picture; 
SWCT=Stroop Word-Color Test; WCST-SF=Wisconsin Card Sorting Test – short form; PVF=Phonologic Verbal Fluency; 
SVF=Semantic Verbal Fluency. *Statistically significant difference 
 
4.2.4 Discussion 
We investigated the complete neuropsychiatric and neuropsychological profile associated 
with motor subtypes of PD in newly diagnosed drug naïve PD patients. Analysing this 
                                         C. Pellicano – Neuropsychiatric and Cognitive symptoms in PD 
 
 
 ______ 
  85 
 
population, we had the opportunity to investigate the cognitive and psychopathological 
aspects without confounding factors, such as disease duration or drug treatment, that 
might affect results. Although previous studies have shown a worse cognitive and 
psychopathological profile of ART than TD patients [14, 16, 18, 28, 29], the main finding of 
our study demonstrates the absence of any cognitive-affective dissimilarities in PD motor 
subtypes groups at the time of the clinical motor onset.  
Most likely, in the early stage of illness cognitive and neuropsychiatric differences from 
ART PD patients are subthreshold, suggesting that such a non-motor symptoms profile 
becomes clinically evident with the progression of PD. This idea is supported, at least to 
the cognitive aspect, by two studies conducted on de novo drug naïve PD patients that did 
not find differences in cognitive profile between PIGD PD motor subtype and TD subtype. 
However, one study found that PIGD patients were more alexithymic than TD ones. This 
discrepancy is probably due to the fact that in our study PD patients have a really short 
duration of illness (less than 1 year) and to the different method to classify motor subtypes 
that has been used.  
The major strength of the present study is the nature of the population investigated (i.e. newly 
diagnosed drug naïve ART PD and TD PD patients). In fact, since dopamine replacement therapy 
may influence or mask neuropsychiatric and cognitive symptoms, studying a group of PD 
patients transiently drug free allows a more naturalistic picture. Additional strength is the 
classification of Kang et al. that we utilized in order to identify motor subtypes of PD. Indeed, 
this methods seems to be the most adequate in the early phase of PD, whereas other 
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classifications [19] consider other hallmarks, such as falls and postural instability, that are more 
frequent in moderate and advanced stages of PD. Finally, the comprehensive neuropsychiatric 
and neuropsychological battery that we used represents a further innovative approach.  
We also acknowledge some limitations of our study. First, the diagnosis of our patients 
has not been confirmed by pathological evidence, but it was given only by positive 
response to dopaminergic therapy. However, the diagnosis is likely to be correct, since all 
patients were diagnosed by two independent movement disorders specialists, both at 
baseline and at follow-up visits performed after 12 and 24 months, when the effect of 
dopaminergic treatment can be evaluated. Second, as far the assessment of motor 
symptoms it was based on the clinical judgment of investigators. More objective motor 
measures may give a better description of patients’ disabilities. 
In conclusion, we showed that in the early stage of PD, motor subtypes are not associated 
with a specific cognitive or neuropsychiatric profile, suggesting that a possible cognitive-
affective differentiation emerges only with the progression of the disease and potentially with 
its interaction with DRT. Therefore, neuropsychological and behavioral evolutions are not 
predictable based on early motor presentation and regular follow-ups are needed to 
investigate their different possible progression. Further studies investigating at which point of 
the disease course the motor subtypes start to diverge are needed. 
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5.1.1 Background 
Progressive Supranuclear Palsy (PSP) is the second most common degenerative 
parkinsonism after idiopathic PD (PD) [1]. Despite of profound neuropathologic 
differences, PSP and PD share similar features, including bradykinesia, loss of dexterity 
and gait disturbances that may complicate differential diagnosis particularly early along 
disease course. Further increasing the diagnostic challenge, recent clinic pathological data 
distinguished several clinical phenotypes of PSP including the PSP-parkinsonism (PSP-P), 
characterized by asymmetric onset of symptoms, tremor, early bradykinesia, non-axial 
dystonia and a response to levodopa, that more closely overlaps with PD than the classic 
description of ‘Richardson’s syndrome’ (PSP-RS) [2]. 
PSP patients in the advanced stages consistently suffer from more severe affective and 
cognitive symptoms, including apathy, depression, executive and visual-spatial deficits, 
than patients with PD [3,4]. The question arises as to whether differences of the pattern 
and severity of neuropsychiatric and neuropsychological symptoms among PD, PSP-P and 
PSP-RS are precociously detectable, along the time span of potential motor symptom 
overlap. 
The results of previous studies are rather contradictory [5-7]. Aarsland et al. described 
increased apathy and disinhibition in PSP patients in comparison with PD patients [5]. Lee 
et al. [6] reported more robust impairment of verbal memory and processing, planning 
and set-shifting in a small cohort of PSP with respect to PD patients, all recruited within 
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the first five years of the illness. Conversely, Borroni et al. [7] found similar 
neuropsychiatric and neuropsychological features in patients suffering from several 
degenerative parkinsonisms (PD, PSP, corticobasal degeneration, dementia with Lewy 
bodies). Data concerning a shorter frame time after onset of motor symptoms are, 
however, missing. Further, a detailed investigation using a complete neuropsychiatric and 
cognitive battery in early PSP-P and PSP-RS patients is still lacking. 
The aim of this study was to investigate comprehensive neuropsychiatric and cognitive 
profile in PSP-P and PSP-RS patients examined within 24 months from motor symptom 
onset, and to compare possible dysfunctions with those found in PD. We hypothesized 
that discrete neuropsychiatric and neuropsychological profiles may be identified in early 
phases of PSP-RS, PSP-P and PD. 
 
5.1.2 Methods 
Participants 
The study was carried out on 180 consecutive patients. Inclusion criteria were: 
a) age between 40-80 years;  
b) diagnosis of degenerative parkinsonism (i.e., PD, PSP-RS and PSP-P), with onset of 
symptoms dating less than 24 months at enrollment.  
Patients were recruited during scheduled visits at the Outpatient Services for Movement 
Disorders of our Institutions in the period between May 2006 and January 2014. 
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Exclusion criteria were:  
a) co-morbidity with major, not stabilized, medical illnesses; 
b) known or suspected history of alcoholism, drug dependence or abuse, other 
neurological disorders, head trauma and mental disorders (apart from mood and anxiety 
disorders) according to the Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition - Text Revision (DSM-IV-TR) [8];  
c) presence of vascular brain lesion or neoplasm at CT or MRI brain scan;  
d) noncompliance with testing procedure. 
All patients were regularly followed-up in our outpatient clinics. Clinical diagnosis of either 
PD (n=155) or PSP (n=25) were confirmed over a minimum of three years follow-up from 
symptom onset, according to the criteria by Gelb et al. [9] and Litvan et al. [1]. Specifically, 
according to diagnostic proposal of PSP phenotypes by Williams et al. [2,10], that is 
currently the reference classification to distinguish between PSP-P and PSP-RS, 14 patients 
were classified as PSP-RS since falls, supranuclear gaze palsy, postural instability and 
levodopa resistance were the predominant clinical features within the first 24 months 
from symptoms onset; eleven patients were classified as PSP-P as they showed in the first 
24 months of the disease abnormality of saccadic eye movements, positive response to 
levodopa, asymmetric onset and postural instability. After a minimum of three years 
follow-up, phenotype of PSP-P patients more closely overlapped the PSP-RS patients with 
severe postural instability (11/11), falls (7/11), supranuclear gaze palsy (11/11) and 
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abnormal saccades (11/11) (Table 5.1.1b). 
Dopamine replacement therapy dosages were calculated as daily levodopa equivalents. 
The following conversion table was applied: 100 mg levodopa = 1 mg pramipexole = 5 mg 
ropinirole = 5 mg rotigotine. Within each group, the number (and %) of subjects receiving 
antidepressant, benzodiazepines and/or antipsychotic therapy was calculated. 
The protocol was approved by the Ethical Committee of the Santa Lucia Foundation IRCCS, 
and each subject signed the informed consent before enrollment.  
Sociodemografic and clinical assessment. 
The demographic and neurological features of patients were collected at enrollment by 
neurologists with expertise on parkinsonisms. The severity of motor symptoms was 
measured by UPDRS-III.  
Within 2 weeks from enrollment, all subjects underwent a SCID-P. Apathy was diagnosed 
according to the adaptation by Starkstein [12] of the Marin criteria [13]. All psychiatric 
diagnoses were made by a senior psychiatrist.  
All participants underwent the following neuropsychiatric scales: HARS, BDI (total score; 
psychic and somatic sub-scores), ARS, PPRS.  
All patients were submitted to a detailed neuropsychological evaluation including: MMSE, 
RIR, RDR, PVF, SVF, CRO, DRO, SWCT,  
All tests have been described in details elsewhere [11]. 
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Neuropsychiatric symptom severity and neuropsychological performances were assessed 
by 3 trained neuropsychologists. Acceptable inter-rater reliability was defined as k>0.80. 
Ancillary assessment of emotion recognition and executive functions  
We also assessed the recognition of facial emotion expressions and executive functions to 
investigate some cognitive and behavioral features possibly linked to apathy. The Penn 
Emotion Recognition Test (PERT) was used to assess facial emotion recognition ability. This 
is a standardized and validated test [14] of 96 color photographs of facial expressions of 
five emotions (happiness, sadness, anger, fear, disgust) and neutral faces. The participants 
viewed the pictures of the facial expressions on the computer screen. Then, they had to 
label the basic emotions by choosing one out of the six possibilities (i.e., anger, sadness, 
disgust, fear, happiness, neutral).  
WCST-SF was used to explore executive function. Data on PERT and WCST-SF were 
available only for a subset of the study sample. In particular, 138 PD, 9 PSP-P and 9 PSP-
RS patients underwent the PERT examination and 154 PD, 11 PSP-P and 11 PSP-RS patients 
the WCST-SF. These data were analyzed only in relationship with apathy. 
Statistical analysis 
Differences in demographic, clinical, neuropsychiatric and neuropsychological features 
among groups were assessed by the chi-squared test for categorical variables and by a 
series of Kruskal-Wallis H tests for continuous variables followed by Mann-Whitney U test 
post-hoc comparisons when appropriate. The neuropsychiatric and neuropsychological 
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independent variables that differed significantly after Bonferroni’s correction for multiple 
comparisons (n=13; i.e., BDI psychic, BDI somatic, HARS, ARS, RIR, RDR, CRO, DRO, PVF, 
SVF, SWCT word reading, SWCT color naming, SWCT interference time; p<0.05/13= 
p<0.0038) among groups were then included in a multivariate logistic regression analysis 
to identify predictors of PSP subtype diagnosis (considered as dependent variable). The 
reference category was diagnosis of PD. 
Further, as an ancillary analysis, we ran a multivariate logistic regression analysis, 
considering PSP-P, PSP-RS and PD diagnosis as dependent variables and including as 
independent variables both neuropsychiatric categorical variables (i.e., diagnosis of 
depression and/or apathy) that were significantly different among groups and the 
predictor(s) selected by the former regression model. Again the reference category was 
diagnosis of PD. 
Finally, in an explorative analysis, differences among groups in scores of PERT and WCST-
SF were assessed by a series of Kruskal-Wallis H tests followed by Mann-Whitney U test 
post-hoc comparisons when appropriate. The Spearman’s rank-order correlation 
coefficient was computed in each group (i.e., PD, PSP-P, PSP-RS) to assess the relationship 
between ARS score and WCST-SF scores. Given the exploratory nature of these last 
analyses, correction for multiple comparisons was not applied and the level of statistical 
significance was accepted as p less than 0.05. 
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5.1.3 Results 
Demographic and clinical features of the study cohort 
The three groups did not differ significantly in any demographic and clinical features (Table 
5.1.1a), apart from UPDRS-III score that was higher in PSP-RS patients in comparison with 
PD patients (Table 5.1.1a).  
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Table 5.1.1b: Demographic and clinical features of patients with PD, PSP-P and PSP-RS. 
Data represent mean±SD (Mean Rank); na= not applicable. 
T0=within 24 months from motor symptoms onset; T1= ≥ three years follow-up from symptom onset. 
 
Neuropsychiatric rating scales  
Table 5.1.2 shows the results of neuropsychiatric rating scales represented by 
continuous values. The three groups differed significantly only in the ARS score. PD 
patients scored better than other two groups. Differences among groups at BDI scores 
did not survive after corrections for multiple comparisons. 
  
Clinical features of PSP patients 
 
PSP-RS T0 
(n = 14) 
PSP-RS T1 
(n = 14) 
PSP-P T0 
(n = 11) 
PSP-P T1 
(n = 11) 
Falls 12 (85.7%) 14 (100%) 0 (0%) 7 (63%) 
Postural Instability 14 (100%) 14 (100%) 3 (30%)  11 (100%) 
Supranuclear gaze 
palsy 
14 (100%) 14 (100%) 2 (18%) 11 (100%) 
Abnormal saccades 14 (100%) 14 (100%) 7 (63%) 11 (100%)  
Asymmetric 
symptoms 
2 (14%) 1 (7%) 9 (85%) 6 (54%) 
Response to 
Levodopa 
2 (14%) 0 (0%) 6 (54%) 2 (18%) 
Speech disturbance 8 (57%) 11 (78%) 3 (30%) 6 (54%) 
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Predictors of PSP diagnosis 
Based on the results of Kruskal-Wallis H tests, we included in the logistic regression 
analysis as potential predictors of PSP subtypes the ARS, RIR, CRO, PVF, SVF and SWCT 
scores. MMSE score was not included, being an index of global cognitive functioning. 
In this logistic regression model, PVF score (OR=0.844, 95%CI=0.742–0.960; p=0.0096) 
significantly predicted PSP-RS diagnosis. ARS score only approached significance in 
predicting PSP-P diagnosis (OR=1.09, 95%CI=0.995–1.21; p=0.06). In a second 
multivariate logistic regression model, we included as independent predictors of PSP 
subtypes the neuropsychiatric diagnoses of apathy and depression and PVF score, 
being the only cognitive predictor identified by the first logistic regression model. In 
accordance with the results of the previous multivariate logistic regression model, PVF 
score (OR=0.769, 95%CI=0.680–0.870; p<0.0001) significantly predicted PSP-RS 
diagnosis. The diagnosis of apathy (OR=9.360, 95%CI=1.654–52.956; p=0.0114) 
significantly predicted the PSP-P diagnosis. 
Ancillary analysis: emotion recognition and executive functions  
PSP-RS patients scored worse than PD at all WCST-SF sub-scores. Further, PSP-RS 
displayed worse score than PSP-P at WCST-SF non-perseverative errors and achieved 
categories. No differences emerged between PD and PSP-P patients (Table 5.1.4). 
Table 5.1.4 shows results of facial emotion recognition of PD, PSP-P and PSP-RS. The 
three diagnostic groups differed significantly in the recognition of facial emotions 
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expressing sadness and in the recognition of neutral faces. PSP-RS patients failed in 
recognizing sadness compared to both PD and PSP-P patients. PD patients recognized 
better than PSP-P neutral faces. 
Additionally, we performed a Spearman's rank-order correlation splitted by group 
(i.e., PD, PSP-P, PSP-RS patients) to assess the relationship between ARS score and 
WCST-SF sub-scores. In PSP-RS group, we found significant correlations between ARS 
score and WCST-SF non-perseverative errors (Rho=0.775, p=0.014), between ARS 
score and WCST-SF perseverative errors (Rho=0.791, p=0.12) and between ARS score 
and WCST-SF achieved categories (Rho=-0.773, p=0.014). No significant correlations 
were found in PSP-P group. In PD group, the only significant correlation observed was 
between ARS score and WCST-SF non-perseverative errors (Rho=0.165, p=0.04).  
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5.1.4 Discussion 
Our results confirm the hypothesis that PSP-P, PSP-RS and PD patients are well 
characterized by peculiar patterns of neuropsychiatric and cognitive symptoms 
detectable from the very early stages of the disease. It is of fundamental importance 
to highlight that the differential diagnosis among these disorders is frequently 
complicated at the onset by the overlap of motor symptoms of parkinsonism. Few 
data are available on this topic in patients with PSP-P and PSP-RS. Here, we applied to 
our cohort a comprehensive neuropsychological and neuropsychiatric battery and a 
formal psychiatric diagnosis, as opposed to previous studies [7,15,16]. In this context, 
our results clearly indicate that, within 24 months from onset of symptoms, there is a 
continuum of severity from the milder PD, throughout PSP-P, to PSP-RS. In particular, 
a poor performance in phonologic verbal fluency may be supportive of a diagnosis of 
PSP-RS, whereas the presence of apathy may predict PSP-P subtype. 
Our findings enhance the previous observation by Lee et al. [6] of more robust 
impairment of verbal memory and processing, planning and set-shifting in PSP as 
compared to PD patients, by showing that significant neuropsychological differences 
between the two disorders may be identified already in the first 24 months after 
symptom’s onset. Conversely, our findings appear in contrast with those by Borroni et 
al. [7], who reported similar patterns of neuropsychiatric and cognitive alterations 
among patients recruited in the early stages of different degenerative parkinsonisms 
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(i.e., PD, PSP, corticobasal degeneration, dementia with Lewy bodies). Several factors, 
including the study design, inclusion/exclusion criteria, and the methodologies 
applied, may contribute at justifying these discrepancies. The study by Borroni et al. 
[7] was designed to identify possible differential patterns of neuropsychiatric and/or 
cognitive symptoms in patients affected by degenerative parkinsonisms matched for 
global condition (MMSE score), whereas we enrolled consecutive patients to get a 
more naturalistic picture of the neuropsychiatric/cognitive features in PSP-RS, PSP-P 
and PD, with the aim of identifying quantitative and qualitative differences 
precociously during disease course. Depression, apathy, executive and visual-spatial 
impairments were, indeed, identified as core neuropsychiatric and 
neuropsychological features of early PSP and PD in both studies, however our 
investigation demonstrates the higher prevalence and severity of these symptoms in 
very early PSP-RS and PSP-P as compared to PD subjects. 
Our data add insights into the clinical variability among patients with the two main 
subtypes of PSP. This is line with post-mortem pathological studies indicating that 
differences in regional burden of tau pathology account for the clinical heterogeneity 
observed in patients with PSP-RS and PSP-P [17,18]. Indeed, patients with PSP-P had 
less severe tau pathology than those with PSP-RS, milder symptomatological 
presentations and relatively better prognosis. Therefore, as stated by Williams and 
Lees [10], PSP-P and PSP-RS represent two separate points on a spectrum of clinical 
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features related to PSP tau pathology. We demonstrate that this assumption is 
reflected by neuropsychiatric and cognitive characteristics as well, PSP-P exhibiting 
milder clinical phenotype than PSP-RS. Following the notion that apathy represents 
one of the most important clinical features of patients with PSP [5], PSP-RS and PSP-P 
did not differ as to severity of continuous score of apathy but a higher frequency of 
formal apathy diagnosis was observed in PSP-P patients. Accordingly, the clinical 
definition of apathy conceptualized by Marin [13] and further adapted by Starkstein 
[12], recognizes behavioral, cognitive and emotional symptoms reflecting disruption 
of distinct aspects of goal directed behavior (GDB) and includes both a lack of inward 
emotional experience and a reduced expression of emotion. GDB impairment is 
sustained by the inability to flexible shifting between behaviors and to maintaining 
purposeful behaviors despite internal or external distractors. Consequently, since the 
cognitive control has been demonstrated as one substrate of apathy itself, reduced 
cognitive flexibility may be one contributor to higher levels of apathy [19]. 
Nevertheless, apathy could not been conceptualize merely as a lack of flexibility but 
rather as a complex process in which emotional and executive impairments 
contribute. Hence, our data demonstrated that PSP-RS patients are more 
compromised in both components. Further, our ancillary data indicated that in PSP-
RS apathy is correlated whit impaired executive functions. Interestingly, PSP-RS and 
PSP-P patients did not show differences in WCST-SF perseverative errors, a 
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component that better describes the cognitive flexibility and is more closely related 
to the ability to respond to changing goals. The underlying mechanisms responsible 
for apathy may be seen as dysfunctions occurring at the level of structures sustaining 
elaboration, execution and control of GDB, such as prefrontal cortex (PFC) and basal 
ganglia [20]. Actually, neuropathological [21] and in vivo imaging studies [22,23] in PSP 
patients, assessed globally as a single disorder, demonstrated dorsal striatum, 
thalamus and midbrain atrophy, cortical atrophy of prefrontal areas and connectivity 
disruption within networks linking brainstem, basal ganglia and cortex. Based on 
cognitive and neuropsychiatric evaluations, our results suggest that the clinical 
hallmarks of such anatomical substrates may be detectable from the very early stages 
of the disease. However, correlation with imaging data goes beyond the purpose of 
our investigation.  
Within this frame of a functional “prefrontal-like” syndrome, interestingly the 
predictor of PSP-RS diagnosis was PVF impairment, measured by a test of linguistic 
abilities that represents also a task of self-activation of cognitive strategies. Indeed, 
the dorsolateral PFC is involved in executive functions as well as in phonological 
processing during word generation (Brodmann Area 46) [24,25]. The correct 
functioning of verbal fluency is associated with activation of a diffuse cortical network 
[26,27]. Schofield and collaborators [27] demonstrated, by neuroimaging techniques 
in confirmed pathological cases of PSP, that cortical atrophy and frontal lobe tau 
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pathology are more severe in PSP-RS than in PSP-P patients. Rittman and colleagues 
recently demonstrated that verbal fluency distinguishes between PSP and PD with 
high sensitivity and high specificity [28]. Our results extend previous reports [28-30] 
showing that verbal fluency tests discriminated well between PSP-RS and PD patients 
already in the first 24 months of the disease. 
In our cohort, PSP-RS patients displayed higher prevalence and severity (although 
statistically only at an uncorrected level) of depression as compared to PD cases. 
Nevertheless, it is of interest that neither severity of depressive symptoms nor clinical 
diagnoses of depression were definitive predictors of PSP-RS diagnosis. This advocates 
for a distinct nature of apathy and depression in PSP, rather than the former being a 
symptom of the latter and stresses the impairment of affective and emotional tone 
since the very early stages in PSP patients. Indeed, our ancillary results on emotion 
processing indicate that the impairment of facial emotion recognition of sadness 
characterizes PSP-RS patients. Nevertheless, PSP-P patients showed a worse 
performance of PD on the recognition of neutral faces due to the attribution of 
emotional saliency to unrecognized neutral expressions. These results further clarify 
our previous observation of compromised emotion processing in PSP and PD patients 
[14]. In fact, on the light of these new results, the difference in emotion recognition 
we have previously described between PD and PSP patients seems to be driven by 
PSP-RS group. In our previous study, we found that PSP patients displayed significantly 
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lower recognition of happy emotional faces. This result did not emerge here. Given 
the shorter disease duration we considered in the present study, we can speculate 
that the impairment in the happiness recognition emerge later in the disease course. 
Taken together these precocious deficits in facial emotion recognition could 
determinate the early difficulties on social and relational abilities.  
We also acknowledge the limitations of our study. Our PSP patients were enrolled 
within Movement Disorders Outpatient Services, suggesting the presence of 
predominant “motor” phenotype of the disease, and therefore possibly 
underestimating the global prevalence and severity of cognitive and behavioral 
impairment in the early PSP population. However, this was indeed our main purpose, 
that is to establish if peculiar neuropsychiatric and neuropsychological profiles may 
precociously help in the differential diagnosis among patient with atypical 
parkinsonism, when very often motor profiles are overlapping. Further, here we did 
not administer behavioral scales to both patients and caregivers. Thus the caregiver 
point of view is lacking in the present study. The relative small sample size of PSP-P 
and PSP-RS patients advocates for further studies on larger series to confirm our 
findings. Finally, we do not have autoptic confirmation of our diagnosis.  
In conclusion, our study demonstrates a different severity of neuropsychiatric and 
cognitive symptoms in PSP-P and PSP-RS with respect to PD, recruited within 24 
months after onset of clinical symptoms. Specifically, we found that verbal fluency 
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impairment and apathy diagnosis are more supportive of diagnosis of PSP-RS and PSP-
P respectively, rather than PD, within 24 months after disease onset. These findings 
indicate that comprehensive cognitive and psychiatric evaluations might be useful and 
cost-effective contributors to the diagnostic work-up of patients with progressive 
parkinsonism in the very early stages. 
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5.2.1 Background 
PSP is one of the most common forms of neurodegenerative atypical parkinsonism [1, 
31]. Two main clinical subtypes of PSP are described: Richardson’s syndrome (PSP-RS), 
characterized by prominent postural instability, supranuclear vertical gaze palsy and 
frontal dysfunction, and PSP-parkinsonism (PSP-P) in which the prominent features are 
asymmetric onset, tremor and moderate initial therapeutic response to levodopa [32]. 
Patients with PSP display also several non-motor symptoms, such as cognitive 
dysfunction [33], neuropsychiatric disorders [34, 35], pain [36], gastrointestinal 
symptoms, fatigue [4], and sleep disorders [37, 38]. Motor and non-motor symptoms 
may result in significant disability and have an impact on health-related quality of life 
(HRQoL) of patients and their care-givers [39]. 
Among all non-motor symptoms that may affect PSP patients, alexithymia and 
anhedonia have not yet been investigated in PSP nor in the two main subtypes of PSP. 
Anhedonia, defined as lowered ability to experience physical or social pleasure, and 
alexithymia, defined as difficulty in identifying and describing feelings and 
distinguishing feelings from bodily sensations of emotional arousal, are two affective 
symptoms frequently reported in PD patients as secondary phenomenon linked to 
depression and apathy severity. In patients with PD these symptoms may arise as a 
primary characteristic [40-43] and they seem to be linked to frontal lobe dysregulation. 
Emotional processing and hedonic ability have a regulatory function on the 
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mechanisms of motivation by promoting transgenerational relationships and 
modulating individual behaviors aimed at increasing the individual’s chances of 
adapting to a community. In patients with PD, these phenomena may have more than 
just theoretical importance and may further complicate the disease, resulting in 
poorer quality of life and reduced social interactions. 
Frontal-subcortical dysfunction play an important role also in the PSP neuropathology 
[44], however no study at present investigated the frequency and severity of 
alexithymia and anhedonia in PSP. Consequently data comparing these symptoms 
between PSP and PD patients or indicating if these two emotional phenomena 
differentiate PSP-RS from PSP-P are lacking. 
On the bases of this background, the aim of this study was to analyze the occurrence 
of alexithymia and anhedonia in PSP-RS and PSP-P compared to PD, early in the disease 
course. 
 
5.2.2 Methods 
Participants 
We enrolled 155 PD, and 25 PSP aged 40-80 years, diagnosed as suffering from 
degenerative parkinsonism, with onset of motor symptoms dating less than 24 months 
at enrollment. All patients were regularly followed in our outpatient clinics. Clinical 
diagnosis of either PD or PSP were confirmed over a minimum of three years follow-
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up from symptom onset, according to the criteria by Gelb et al. [9] and Litvan et al. 
[45]. Patients were classified as being affected by PSP-P (n=11) or PSP-RS (n=14) 
according to the criteria of Williams and colleagues [2, 10]. 
Patients with co-morbidity for major not stabilized medical illnesses, known or 
suspected history of alcoholism, drug dependence or abuse, other neurological 
disorders, head trauma and mental disorders (apart from mood and anxiety disorders) 
according to the DSM-IV-TR [46], and presence of vascular brain lesion or neoplasm at 
CT or MRI brain scan were excluded from the study. 
Dopamine replacement therapy dosages were calculated as daily levodopa 
equivalents. The following conversion table was applied: 100 mg levodopa = 1 mg 
pramipexole = 5 mg ropinirole = 5 mg rotigotine. 
The protocol was approved by the Ethical Committee of the Fondazione Santa Lucia 
IRCCS - Rome, and each subject signed the informed consent before enrollment. 
Clinical, neuropsychiatric and neuropsychological examinations 
Within 2 weeks from enrollment, all participants underwent complete clinical, 
neuropsychiatric and neuropsychological evaluations [see section 5.1.2].  
In this study we submitted PSP and PD patients to an additional neuropsychiatric 
evaluation to investigate alexithymia and anhedonia. In particular, hedonic tone was 
evaluated using the SHAPS and alexithymia was assessed by the TAS-20.  
Neuropsychiatric and neuropsychological evaluations were performed by 3 trained 
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neuropsychologists. Acceptable inter-rater reliability was defined as k>0.80. 
Statistical analysis 
Differences in sociodemographic and neuropsychiatric features among groups were 
assessed by the chi-squared test for categorical variables and by a series of univariate 
analyses of variance (ANOVAs) for continuous variables followed by Fisher’s Least 
Significant Difference (LSD) test post-hoc comparisons when appropriate. 
The level of statistical significance was defined as p <0.05. 
 
5.2.3 Results 
Demographic, clinical, neuropsychiatric and cognitive features of the study cohort 
The three groups did not differ significantly in any demographic feature apart from 
UPDRS-III that was higher in PSP-RS patients in comparison with PD patients (Table 
5.2.1). As we have previously described in the same cohort in our antecedent study 
(for details, see 5.1.3), the three groups differed significantly in the apathethic 
symptoms severity and in several neuropsychological domains. PSP-RS were more 
depressed than two other groups and the diagnosis of apathy were more frequent in 
both PSP subtype diagnoses respect to PD patients.  
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Table 5.2.1 Demographic and clinical characteristics of patients with PD, PSP-P and PSP RS. 
Data represent mean±SD; PD = PD; PSP-P = Progressive Supranuclear Palsy-Parkinsonism; PSP-RS = Progressive 
Supranuclear Palsy-Richardson syndrome; UPDRS-III = Unified PD Rating Scale - Part III; na = not applicable;  PLSD 
= Fisher’s Protected Least Significant Difference. 
 
Alexithymia and anhedonia rating scales and diagnosis 
The three groups differed significantly in the TAS-20 total, F1 and F2 scores. Both PSP-
P and PSP-RS patients scored worse than PD ones at TAS-20 total and F1 subscale; only 
PSP-RS had significantly higher F2 score than PD group (Table 5.2.2). 
Significant differences among PD, PSP-P and PSP-RS were found in the SHAPS scores: 
PSP-P and PSP-RS patients had significantly higher anhedonic symptoms than PD 
patients. As to neuropsychiatric diagnoses, alexithymia was more frequent in both PSP 
subtypes respect to PD patients (Table 5.2.2). 
  
Characteristics 
PD 
(n=155) 
PSP-P 
(n=11) 
PSP-RS 
(n=14) 
F df 
ANOVA  
P 
Post Hoc analysis (PLSD) 
P 
PD 
vs. 
PSP-P 
 
P 
PD vs. 
PSP-RS 
 
P 
PSP-P 
vs. 
PSP-RS 
Age (Years) 67.2±7.47 65.4±6.6 68.9±7.5 0.714 2 0.491 Na Na na 
Disease 
duration 
(months) 
15.3±8.4 15.3±9.4 18.75±5.2 1.169 2 0.313 Na Na na 
Education 
(Years) 
10.5±4.5 11.9±5.2 8.8±3.9 1.524 2 0.221 Na Na na 
UPDRS-III score 15.9±9.3 21.2±11.3 25.0±6.5 4.760 2 0.01 0.09 0.008 0.403 
 PD PSP-P PSP-RS χ2 df p    
Sex (Male, %) 
84  
(54.2%) 
7   
(63%) 
6   
(42.8%) 
1.117 2 0.573 Na Na na 
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Table 5.2.2: Alexithymia and Anhedonia in patients with PD, PSP-P and PSP-RS. 
Data represent mean±SD. PD = PD; PSP-P = Progressive Supranuclear Palsy-Parkinsonism; PSP-RS = Progressive 
Supranuclear Palsy-Richardson syndrome; TAS-20 = Toronto Alexithymia Scale-20-item; F1 = TAS-20 difficulty 
identifying feelings; F2 = TAS-20 difficulty describing feelings; F3 = TAS-20 externally oriented thinking; na = not 
applicable; *Significant at p<0.05. 
 
5.2.4 Discussion  
To date, no data are available on alexithymia and anhedonia in patients with PSP-P and 
PSP-RS. Our results show clearly, for the first time, that PSP-P and PSP-RS patients are 
characterized by peculiar affective symptoms, already in the early stages of the 
diseases.  
Indeed, PSP-P and PSP-RS show higher rate of alexithymia and alexithymic symptoms 
than PD. In particular, alexithymic severity and difficulty in identifying feelings may be 
Variables 
PD 
(n=155) 
PSP-P 
(n=11) 
PSP-RS 
(n=14) 
F df P 
Post Hoc analysis 
P 
PD vs. 
PSP-P 
P 
PD vs. 
PSP-RS 
P 
PSP-P 
vs. 
PSP-
RS 
TAS-20 total 46.2±11.7 55.2±18.1 59.2±11 8.790 2 0.0002* 0.0182* 0.0004* 0.4213 
TAS-20 F1 12.2±5.8 16.4±7 17.6±11.1 5.823 2 0.0036* 0.0349* 0.0055* 0.6700 
TAS-20 F2 13.4±5.9 16.4±7.6 18.7±7.1 5.235 2 0.0062* 0.1202 0.0038* 0.3486 
TAS-20 F3 20.5±5.6 22.4±9.5 22.9±7.3 1.262 2 0.2856 na na na 
SHAPS 0.439±0.8 1.2±1.5 1±1 5.464 2 0.005* 0.008* 0.0362* 0.6241 
 PD PSP-P PSP-RS χ2 df P    
Alexithymia 
(% Y) 
12.9% 54.5% 50% 21.027 2 <0.0001* na na na 
Anhedonia 
(% Y) 
75% 12.5% 12.5% 1.094 2 0.5787 na na na 
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a specific aspect of PSP (PSP-P and PSP-RS), whereas the difficulty in describing feelings 
well characterizes only PSP-RS subtype in comparison to PD. In general, the presence 
of alexithymia distinguished PSP group from PD group, but not the two subtypes of 
PSP. Therefore, this finding supports the idea that alexithymic status and 
symptomatology could be a non-motor index of parkinsonism rather than PD in the 
early stage of onset of motor symptomatology. Similar results were obtained for 
anhedonia: anhedonia severity was higher in PSP-P and PSP-RS than in PD, despite no 
differences were found in the frequency of its diagnosis. 
In general, our results translated in the daily life of PSP patients, meaning that these 
patients experience greater social, relational and behavioral difficulties than patients 
with PD. In fact, people with alexithymic status or symptomatology are unable to 
cognitively elaborate emotions or conceptualize them by mental imaging or words. 
Therefore, in PSP alexithymia, which includes deficient empathetic ability, could lead 
to great impairment of emotional processing and organizing that can seriously 
compromise communicative and interactive abilities of patients. This may have an 
impact on social intelligence, because the ability to understand emotions has a 
significant role in good social functioning.  
The same result is product by anhedonia since, in a broader way, we can say that 
anhedonia is the inability to desire gratification. In fact, anhedonic patients experience 
an inadequate way of relating to the environment, which manifests itself with a 
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tendency to isolation. In other words, in PSP patients anhedonia can act not only on 
the psychological perception of pleasure to something, but also affects the willingness 
of patients leading to annihilation of any useful energy and interest to perform the 
most common and basic human activities. 
This work adds further insights into the clinical variability between PSP and PD patients. 
In particular, PSP-P and PSP-RS represent two separate manifestations of PSP tau 
pathology [18]. In our previous study, we demonstrated that this assumption is 
reflected by neuropsychiatric and cognitive evaluations (see section 5.1). Now, our 
new results corroborate even more such an idea. In fact, we showed that alexithymia 
and anhedonia are common in both PSP subtypes and differentiate them from PD, 
which seems to be less affected from these phenomena. Moreover, a specific 
dimension of alexithymia, that is difficulty in describing feeling, seems to be more 
characterizing the PSP-RS. In particular, this group shows significant differences also in 
alexithymic F2 subscale (difficulty describing feelings) respect to PD. Accordingly to 
differences in regional burden of tau pathology observed in post-mortem pathological 
studies [17, 18] this could be due to more severe cortical atrophy and frontal lobe tau 
pathology in PSP-RS than PSP-P [27]. This latter justifies the increased difficulty in 
verbal fluency that we have found in PSP-RS patients (see section 5.1) and thus the 
difficulty in describing feelings. 
Moreover, it is well known that patients with clinically established PSP exhibit distinct 
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patterns of atrophy, particularly affecting the frontal lobe and subcortical structures 
than PD [10, 23, 44, 47, 48], explaining our findings of greater impairment of affective 
and hedonic abilities in PSP patients, since alexithymia and anhedonia seem to be 
related to dysfunctions in these circuits. In particular, prefrontal, limbic and striatal 
abnormalities may significantly contribute to deficits in the effortful emotion 
regulatory process and in the emotion processing [40, 41, 49, 50]. 
Our study suffers from some limitations: first, our PSP patients were enrolled within 
Movement Disorders Outpatient Services, suggesting a predominant “motor” 
phenotype of the disease, and therefore possibly underestimating the prevalence and 
severity of affective impairment in the early PSP population; second the relative small 
sample size of PSP-P and PSP-RS patients advocates for further studies on larger series 
to confirm our findings. 
In conclusion, PSP-P and PSP-RS exhibit worse alexithymic and anhedonic features than 
PD. Our results support the hypothesis that altered hedonic capacity and alexithymic 
symptoms mirror a basic neurophysiological dysfunction occurring precociously in PSP, 
therefore their identification could orient the diagnosis toward PSP cases; particularly 
difficulty in describing feelings could help to identify PSP-RS patients. Hence, our 
findings suggest that comprehensive psychiatric evaluations might be useful for 
diagnostic and therapeutic processes of PSP patients since the early stages of the 
disease. 
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6. Advanced PD patients 
6.1 Sociodemographic, neuropsychiatric and cognitive characteristics of pathological 
gambling and impulse control disorders NOS in PD 
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found at: 
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6.1.1 Background 
The inability to resist an impulse, drive, or temptation to perform an act that is harmful 
to the person or others, defined as "impulse control disorder" (ICD), interferes with 
major areas of life functioning. Originally, ICD pertained to a variety of aberrant 
behaviors, including pathological gambling (PG). However, a distinction between PG 
and other variants of ICD (ICD-NOS), was initiated in the Diagnostic and Statistical 
Manual of Mental Disorders, IV Edition - Text Revision (DSM-IV-TR) [1] and defined in 
the 5th Edition of the DSM (DSM-5) that categorizes PG within the "Addiction and 
Related Disorders " Section [2].  
ICDs have been identified in subjects suffering from PD [3, 4] with significantly higher 
prevalence than general population [5, 6]. Despite of consistent evidence for the 
association between ICDs and multiple demographic, clinical and therapeutic traits in 
PD [6-10], several issues remain unclear, particularly with respect to differences of 
neuropsychiatric and cognitive profile between PG and ICD-NOS.  
The primary aim of the present study was twofold: first, to clarify the differences of 
neuropsychiatric profile of PD patients with PG as compared to those with ICD-NOS or 
without ICD (No-ICD) by means of a comprehensive approach based on both 
categorical and continuous classifications; second, to investigate the relationships 
between aberrant behaviors and specific cognitive functions in PD patients by using a 
complete neuropsychological battery.  
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We hypothesized that specific features and severity of neuropsychiatric profile could 
differentiate among PG, ICD-NOS and No-ICD. Conversely, we postulated the lack of 
difference of cognitive functions among the three conditions. 
 
6.1.2. Methods 
Participants and Study Design 
The study was carried out on 155 PD patients aged between 35 and 80 years, 
diagnosed according to the criteria by Gelb et al. [11]. Participants were recruited 
consecutively during scheduled visits at the Outpatient Services for Movement 
Disorders of the “Fondazione Santa Lucia, IRCCS” and the “Sapienza Università di Roma 
- Ospedale Sant'Andrea”, between January 2011 and December 2012. Three 
neurologists with expertise in PD were in charge of diagnosis and selection of patients. 
The protocol was approved by the Ethical Committee of the “Fondazione Santa Lucia, 
IRCCS” and each subject signed an informed consent before enrollment. All patients 
were under stable dopaminergic therapy for at least 2 months before enrollment. 
Dopamine replacement therapy was calculated as daily levodopa equivalents. If the 
case of dopamine agonists, the following conversion table was applied: 100 mg 
levodopa = 1 mg pramipexole = 5 mg ropinirole = 5 mg rotigotine. Within each group, 
the number (and %) of subjects receiving antidepressant, benzodiazepines and/or 
antipsychotic therapy was calculated. Overall disease severity was staged according to 
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the modified H&Y scale [12]. The UPDRS-III was used to evaluate motor disability [13]. 
Exclusion criteria were as follows: 
1. Co-morbidity with major medical illnesses. 
2. Co-morbidity with primary neurological disorders such as stroke, Alzheimer's 
disease, head trauma with loss of consciousness, and others.  
3. MMSE score <26.  
4. Diagnosis of PD-dementia according to the clinical diagnostic criteria of the 
Movement Disorder Society [14] 
5. Diagnosis of schizophrenia or bipolar disorder prior to the onset of motor 
symptoms.  
6. CT or MRI evidence of significant focal cerebral abnormalities suggesting a 
secondary nature of parkinsonism. 
All subjects were submitted to the SCID-P according to the DSM-IV-TR criteria[1]. A 
senior research psychiatrist made all psychiatric diagnoses. Symptoms of ICD were 
identified by means of the Questionnaire for Impulsive-Compulsive Disorders in PD 
(QUIP) [15] while the formal diagnosis of ICD was based on the DSM-IV-TR criteria. 
Patients were divided into 3 groups (i.e. PG, ICD-NOS and NoICD). If the case of 
multiple ICDs, the presence of PG drove inclusion of subject into the PG subgroup. 
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Neuropsychiatric and Cognitive Assessment 
Four clinical neuropsychologists made all neuropsychiatric and neuropsychologic 
assessments. The neuropsychiatric evaluation included HDRS, HARS, SHAPS, ARS, PPRS 
and the Euro-QoL scale (ERS) [16] for measuring health-related quality of life. 
All patients were submitted to a neuropsychologic evaluation including MMSE, RIR, 
RDR, PVF, SVF, CRO, DRO, WCST-SF and SWCT. 
Statistical Analysis 
Differences among the 3 groups were assessed by the chi-squared test for categorical 
variables and by a series of analyses of variance (ANOVAs) for continuous variables. 
Post-hoc comparisons were performed using Fisher's test for variables showing 
statistically significant differences on ANOVAs. For all tests, the level of significance 
was set at p<0.05. 
 
6.1.3 Results 
Demographic and Clinical Features 
The demographic, neurological, and neuropsychiatric features of the study cohorts are 
summarized in Table 6.1.1. There were 21 (14%) PG subjects (pure PG=10; PG+ICD-
NOS=11), 36 (23%) ICD-NOS subjects (hypersexuality=16; compulsive shopping=3; 
binge eating=10; hypersexuality+binge eating=4; hypersexuality+compulsive 
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shopping=1; compulsive shopping+binge eating=1; hypersexuality+compulsive 
shopping+binge eating=1) and 98 (63%) No-ICD subjects. 
PG subjects were significantly younger than ICD-NOS and No-ICD ones. Moreover, ICD-
NOS subjects were significantly younger than No-ICD ones. PG patients had younger 
age at symptom onset with respect to the other 2 groups. PG and ICD-NOS subjects 
had longer disease duration and were taking significantly higher total daily levodopa 
equivalents (both levodopa and dopamine agonists) than No-ICD ones. Conversely, 
there were no significant differences of prevalence of therapy with antidepressant, 
benzodiazepines or antipsychotics among the 3 groups.  
There were no differences among the 3 groups as to sex, educational attainment, H&Y 
stage, UPDRS-III score and the prevalence of major depression, minor depression or 
generalized anxiety disorder. 
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Neuropsychiatric Assessment 
As shown in Table 6.1.2, PG subjects had significantly higher scores at the HDRS and 
HARS with respect to the other 2 groups. Moreover, PG subjects displayed a trend 
toward higher score at the SHAPS with respect to No-ICD ones. 
Both PG and ICD-NOS subjects had significantly higher PPRS total score than No-ICD 
ones. Analysis of the different PPRS domains showed that both PG and ICD-NOS groups 
had significantly higher “sleep disturbances” and “sexual preoccupation” scores with 
respect to NoICD. Further, ICD-NOS patients had significantly higher “visual 
hallucination” and “paranoid ideation” PPRS domain scores, and significantly higher 
ERS score with respect to the other 2 groups. They also displayed a trend toward 
significance for higher PPRS “illusions” score. Finally, there were no differences among 
groups in the ARS and in the “confusion” domain of the PPRS. 
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Table 6.2.2: Psychopatologic Scores 
 
NoICD 
(n=98) 
Mean 
± SD 
PG 
(n=21) 
Mean ± 
SD 
ICD-
NOS 
(n=36) 
Mean 
± SD 
F df P 
Post Hoc analysis 
P 
PG vs. 
NoICD 
P 
ICD-NOS 
vs. 
NoICD 
P 
PG vs. 
ICD-
NOS 
HARS 8±5.7 13.6±6.4 8.9±7 7.128 2 0.0011* 0.0002* 0.4435 0.0065* 
HDRS 7.2±5 11.2±5.6 8.4±4.6 5.499 2 0.0049* 0.0013* 0.2393 0.0435* 
SHAPS 0.4±0.9 0.9±1.7 0.5±0.7 2.315 2 0.1022 0.0342* 0.8264 0.0883 
ARS 8±6.3 8.9±5.3 7.1±6.3 0.570 2 0.5665 0.5324 0.4797 0.2950 
PPRS Total 6.6±0.9 7.5±1.3 7.9±1.9 16.140 2 <0.0001* 0.0042* <0.0001* 0.2013 
PPRS Visual 
Hallucinations 
1.1±0.2 1±0.2 1.2±0.4 3.181 2 0.0443* 0.8421 0.0171* 0.0613 
PPRS Illusions 1±0.2 1±0.2 1.2±0.5 2.921 2 0.0569 0.8082 0.0176* 0.1382 
PPRS 
Paranoid 
Ideation 
1±0.1 1.1±0.3 1.2±0.4 5.259 2 0.0062* 0.1657 0.0019* 0.3072 
PPRS Sleep 
Disturbances 
1.3±0.6 1.7±0.6 1.7±0.8 7.051 2 0.0012* 0.0155* 0.0012* 0.8352 
PPRS 
Confusion 
1±0.1 1±0.2 1±0.2 0.254 2 0.7759 0.4801 0.8133 0.6519 
PPRS Sexual 
Preoccupation 
1.1±0.4 1.5±0.8 1.6±0.9 8.855 2 0.0002* 0.0089* 0.0002* 0.7244 
ERS 7±1.1 7.5±1.5 7.7±1.7 3.694 2 0.0271* 0.1315 0.0124* 0.6397 
SD=standard deviation; df=degrees of freedom; HARS=Hamilton Anxiety Rating Scale; HDRS=Hamilton Depression 
Rating Scale; SHaPS=Snaith-Hamilton Pleasure Scale; ARS=Apathy Rating Scale; PPRS=Parkinson Psychosis Rating 
Scale; ERS=Euro-QoL Scale; *Statistically significant differences. 
 
Cognitive Assessment 
Table 6.1.3 shows the lack of significant difference in any cognitive domain among the 
3 groups. It is important to highlight that possibility of false negative results was 
excluded as all differences were far below the level of significance (p>0.1 for all 
comparisons). 
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6.1.4 Discussion 
The present results demonstrate higher severity of depressive and anxious symptoms 
in PG patients with respect to the other groups (Table 6.1.2). This clarifies doubts 
raised from conflicting or inconclusive results in the literature [5, 17, 18] and allows to 
draw specific neuropsychiatric distinctions between PG and ICD-NOS. Our results also 
show more specific and severe psychotic symptoms in ICD-NOS subjects with respect 
to PG and No-ICD ones (Table 6.1.2). These findings may depend upon hypersensitivity 
of mesolimbic postsynaptic receptors to dopamine replacement therapy. Indeed, 
recent functional neuroimaging studies demonstrated reduction of dopamine re-
uptake sites in the ventral striatum of PD patients with ICD [19, 20], therefore 
suggesting partial mesolimbic dopaminergic denervation.  
The results of the present study also show the lack of relationship between ICD (both 
PG and ICD-NOS) and cognitive performances in undemented PD patients. These 
findings strongly argues against a causative link between specific cognitive dysfunction 
and ICD. 
Our results confirm and extend previous reports on the association between 
impulsive/compulsive behaviors and some demographic, clinical or therapeutic 
features of PD [6-9, 17] (Table 6.1.1). Thus, daily dose of dopamine replacement 
therapy was significantly higher in PG and ICD-NOS as compared to No-ICD patients, 
although there were no differences between PG and ICD-NOS. These findings suggest 
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that excessive pharmacological stimulation of non-motor dopaminergic pathways may 
play a fundamental role in the development and maintenance of ICD in general, but 
not in determining the specific phenotype of aberrant behavior. This is consistent with 
an “overdosing” behavioral effect of dopaminergic drugs, and dopamine agonists in 
particular, on subcortical mesolimbic pathways in PD patients with ICDs [19].  
Conversely, an age-dependent gradient of probability of developing different variants 
of ICD was found, younger subjects being particularly at risk for PG. This suggest that 
interaction between biological (age) and exogenous (dopaminergic drugs) factors may 
be relevant to determine the specific phenotype of ICD behavior in PD patients. Finally, 
the lack of relationships between ICD (any variant) and disease stage or severity of 
parkinsonian motor symptoms confirms previous reports, and indicate that PD 
patients should be monitored for ICD since the early clinical stages and independently 
from the rate of progression of motor symptoms. 
The positive and negative results of the present study were strengthened by the use 
of rigorous psychiatric diagnostic criteria associated with specific neuropsychiatric and 
neuropsychologic scales. We acknowledge, however, that the moderate sample size 
did not allow specific analysis of the neuropsychiatric and cognitive features of the 
different behavioral variants of ICD-NOS and this have to be considered as a limitation 
of the present study.  
In conclusion, the results of the present study clarify and extend previous knowledge 
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on the association between different phenotypic variants of ICD and multiple 
demographic, clinical and therapeutic domains in PD patients. In particular, we 
demonstrate different neuropsychiatric profiles between PG and ICD-NOS indicating 
that development of PG is coupled with significantly more severe depression and 
anxiety, and that development of impulsive/compulsive behaviors occurs 
independently from any selective impairment of cognitive function. This suggests that 
PD patients developing PG may represent a subset of subjects with distinct 
neurochemical and neuropathologic features.  
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6.2 Morphometric changes in the reward system of PD patients with impulse control 
disorders 
 
Clelia Pellicano1,2, Flavia Niccolini1,3, Kit Wu1, Sean S. O’Sullivan4, Andrew D. 
Lawrence5, Andrew J. Lees 4, Paola Piccini1 and Marios Politis1,3 
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Brain Sciences, Hammersmith Campus, Imperial College London, London, United Kingdom 
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Sapienza University, Rome, Italy 
3Neurodegeneration Imaging Group, Department of Basic and Clinical Neuroscience, 
Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, 
United Kingdom 
4Reta Lila Weston Institute of Neurological Studies, University College London, UK 
5Cardiff University Brain Research Imaging Centre (CUBRIC) and School of Psychology, 
Cardiff University, UK 
 
 
Hereunder we report an excerpt of the study. Full-text of the related article can be 
found at: 
https://www.ncbi.nlm.nih.gov/pubmed/26410743 
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6.2.1 Background 
The mechanisms underlying the development of ICDs in PD are still poorly understood 
and their management can be challenging [21].  
PET and fMRI studies have demonstrated mesocortical and limbic network 
dysfunction during valuation (risk-reward processing), motivation, decision-making 
and inhibitory control in PD patients with ICDs [22-27]. A SPECT connectivity analysis 
found specific functional disconnection between anterior cingulate cortex (ACC) and 
striatum in PD patients with pathological gambling [24]. These findings suggest that 
there is dysregulated reward processing in PD patients with ICDs including enhanced 
ventral striatum activity and poor cortical inhibitory control. Antecedent anatomical 
differences might underlie an increased vulnerability to ICDs [28]. If this is the case, 
structural MRI studies may help in clarifying why some patients are at greater risk for 
impulsivity. Alternatively, they may reflect the impact of non-physiological 
dopaminergic stimulation on the brain in sensitized individuals [29]. Recent data 
demonstrated reduced local gyrification index and grey matter atrophy in 
orbitofrontal cortex of PD patients with pathological gambling [30] and significant 
cortical thinning in fronto-striatal circuitry of PD patients with ICDs [31]. 
In this study we have used high-resolution structural 3-Tesla MRI and FreeSurfer 
automated reconstruction of cortical thickness (CTh) and subcortical nuclei, to 
investigate macrostructural alterations in mesocorticolimbic regions in medicated PD 
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patients with ICDs relative to PD patients without ICDs and healthy control 
participants. We hypothesized that the presence of ICDs would be associated with 
structural alterations in brain reward circuitry. 
 
6.2.2 Methods 
Participants and clinical characteristics  
Thirty-six non-demented patients with PD who fulfilled the Queen Square Brain Bank 
criteria [11] were recruited from specialist movement disorders clinics at Imperial 
College Healthcare NHS Trust and King’s Health Partners (Table 6.2.1).  
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Table 1. Demographic and Clinical features of the study cohort. 
 HC PD with ICDs PD without ICDs 
No 24 18 18 
Age (years ± SD) 55.0 (±8.4) 56.6 (±9) 55.8 (±8) 
Sex  20M / 4F 16 M / 2F 14 M / 4F 
Age at onset (years ± SD) − 46.2 (±10) 49.4 (±8) 
Disease Duration1(years ± SD) − 10.4 (±4.8) 6.4 (±4.8)* 
H&Y OFF2(mean ±SD) [range] − 2.3 (±0.5)[2-3] 1.9 (±0.5)[1-3]* 
UPDRS-III OFF3(mean ± SD) [range] − 43 (±11) [17-71] 28 (±10) [7-47]** 
MMSE (mean ±SD) 29.6 (±0.5) 29.3 (±1.2) 29.6 (±0.7) 
Daily LEDtotal4(mg ± SD) − 789 (±370) 560 (±418) 
Daily LEDlevodopa (mg ± SD) − 644 (±411.5) 415 (±397.3) 
Daily LEDDag5 (mg ± SD) − 154 (±144) 124 (±125) 
Patients treated with DAg (%) − 12 (66.7%) 11(61.1%) 
1From time of first appearance of PD motor symptoms;2H&Y: Hoehn and Yahr; 3UPDRS-III: Unified PD Rating Scale 
Part-III. 4LED: Levodopa Equivalent Dose; 5DAg: dopamine agonist.*P<0.05; **P< 0.01 
 
Eighteen of these satisfied the diagnostic criteria for one or more current ICDs 
according the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s 
Disease (QUIP) [15] and a formal diagnosis of ICD was made on the basis of the DSM-
IV-TR following a semi-structured interview. Different type of ICDs including: 
pathological gambling, compulsive shopping, hypersexuality, binge eating, dopamine 
dysregulation syndrome, and problematic internet use were described by the patients 
and half had more than one ICD (Table 6.2.2).  
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Table 6.2.2. PD patients with ICDs. 
Subject Sex Age Type of ICDs 
Daily LEDlevodopa 
(mg) 
Daily LEDDag 
(mg) 
1 M 66 PG, CS 400 240 
2 M 56 PG 1000 160 
3 M 50 HS, PG, BE 0 200 
4 M 67 PG 800 160 
5 F 64 PG 1166 300 
6 M 45 CS 1000 0 
7 M 41 HS 1366 0 
8 M 47 HS 400 0 
9 M 60 CS, BE, PIU 600 300 
10 M 59 PG 0 533 
11 M 54 HS 260 240 
12 M 54 HS, PG, BE, CS 867 80 
13 M 66 HS, CS 533 0 
14 F 56 HS, BE, CS 0 200 
15 M 74 PG, DDS 866 160 
16 M 51 HS,CS 1000 200 
17 M 46 HS, BE 500 0 
18 M 63 BE 833 0 
PG=pathological gambling; CS=compulsive shopping; HS=hypersexuality; BE= binge eating; PIU=problematic 
internet use; DDS=dopamine dysregulation syndrome; LED: Levodopa Equivalent Dose; DAg: dopamine agonist 
 
The other 18 PD patients had no history of ICDs. Twenty-four healthy controls (HC) 
matched for age and sex with no history of neurological or psychiatric disorders served 
as the control group. 
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Motor symptom severity was assessed with the UPDRS-III [13] and staged with H&Y 
[12]. Global cognitive status was assessed by MMSE in all participants. Dopamine 
replacement therapy was calculated as daily levodopa equivalents (LED) for each 
patient based on theoretical equivalence to levodopa [32]. 
The study was approved by the institutional review boards and the local research 
ethics committee. Written informed consent was obtained from all study participants 
in accordance with the Declaration of Helsinki. 
Data acquisition and processing  
All participants were scanned on a 3-Tesla Philips Intera whole-body MRI scanner. A 
T1-weighted three-dimensional magnetization-prepared rapid acquisition gradient-
echo (MPRAGE; time echo: 4.6 ms; time repetition: 9.7ms; field of view: 240 ms; voxel 
size= 1 x1 x 1 mm) was acquired.  
FreeSurfer’s image analysis suite (version 5.3.0 http://surfer.nmr.mgh.harvard.edu) 
processing pipeline was used to derive measures of cortical thickness (CTh) and deep 
grey matter (GM) nuclei volume. This process consists of several stages, detailed 
elsewhere [33, 34].  
We considered CTh measures of 10 selected cortical regions belonging to the 
mesocorticolimbic network and the following subcortical GM nuclei: caudate, 
putamen, globus pallidum, hippocampus, nucleus accumbens and amygdala (Table 
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6.2.3). All individual volumes were normalized for intracranial volume (ICV) 
automatically generated by FreeSurfer. Since no laterality was observed and for 
minimizing the number of comparisons, average hemispheric CTh and deep GM values 
were processed in the statistical analysis. 
Statistical analysis 
Statistical analyses were performed using Statistical Package for Social Science version 
21.0. (SPSS, Inc. Chicago, IL, USA). For all variables, homogeneity and Gaussianity were 
tested with Bartlett and Kolmogorov-Smirnov tests. Demographic and clinical 
characteristics among groups were assessed by univariate analysis of variance with 
post-hoc Bonferroni’s correction for continuous variables and by Chi-square test for 
categorical variables. Differences in clinical characteristics between PD patients with 
and without ICDs were analyzed using unpaired t-test and Chi-square test where 
appropriate. First, we run a one-way multivariate analysis of variance (MANOVA) with 
a single independent variable (i.e., group) with three levels to investigate differences 
in CTh and subcortical GM nuclei volume among groups. The omnibus level of 
significance for MANOVA was set at P<0.05. If the MANOVA was significant, we 
conducted a series of one-way ANOVAs, followed by Bonferroni’s multiple-
comparisons post-hoc tests (P<0.05 Bonferroni corrected), to compare means among 
groups. The level of significance was set at P<0.05 for the ANOVA comparative 
measurements. Additionally, even though age was not significantly different among 
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groups, the multivariate analysis was repeated adding age as covariate. Subsequently, 
in order to clarify our main research question, MRI data between the groups of PD 
with ICDs and PD without ICDs were compared for F and P values with multivariate 
analysis of co-variance (MANCOVA) using disease duration, and UPDRS-III score as 
covariates. If MANCOVA P values were significant (P <0.05), we calculated a series of 
one-way ANOVAs, to compare means between-group. The level of significance was 
set at p <0.05 for the ANOVA comparative measurements. Although we didn’t find a 
significant difference between the groups of PD with ICDs and PD without ICDs in total 
daily LED, we run an additional MANCOVA between PD groups using total daily LED, 
disease duration and UPDRS-III as covariates. Additionally, even though age was not 
significantly different among groups, all the multivariate analysis were repeated 
adding age as covariate. We investigated differences in clinical and morphometrics 
data between PD patients with one ICDs and PD patients with multiple ICDs using 
MANOVA.  Further, we ran linear regression analysis split by group (i.e., PD with 
ICDs; PD without ICDs) between total daily LED and those brain structures showing 
significant differences between PD groups by the results of MANCOVA. All data are 
presented as mean±SD, and the level α was set for all comparisons at P<0.05, 
corrected. 
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6.2.3 Results 
Structural changes: comparisons to normality 
We found significant differences in MRI measures among the three groups (F2,57=2.62, 
P=0.001, η2p=0.494). Bonferroni’s post-hoc tests showed volume loss in the nucleus 
accumbens of both PD patient groups: with ICDs (P=0.001) and PD patients without 
ICDs (P=0.001) when compared to healthy controls. PD patients with ICDs showed 
further significant atrophy in caudate (P=0.02), hippocampus (P=0.04) and amygdala 
(P=0.03) compared to healthy controls. Cortical thickness in rostral anterior cingulate 
and frontal pole was increased in PD patients with ICDs compared to the control group 
but the differences failed to reach corrected levels of statistical significance (Table 
6.2.3). Covarying for age did not influence results. 
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Table 6.2.3: Cortical thickness and subcortical nuclei volume in PD patients with ICDs compared to the 
group of healthy controls.  
 Healthy controls PD with ICDs 
P 
values* 
% Change (PD ICD  
vs. HC) 
Medial orbitofrontal cortex 
(mm; mean±SD) 
2.21 (±0.04) 2.24 (±0.04) >0.10 +1.4 
Lateral orbitofrontal cortex 
(mm; mean±SD) 
2.53 (±0.04) 2.52 (±0.05) >0.10 -0.4 
Frontal pole (mm; mean±SD) 2.56 (±0.05) 2.70 (±0.06) >0.10 +5.5 
Superior frontal cortex (mm; 
mean±SD) 
2.63 (±0.04) 2.54 (±0.05) >0.10 -3.4 
Rostral middle frontal cortex 
(mm; mean±SD) 
2.26 (±0.03) 2.29 (±0.04) >0.10 +1.3 
Parahippocampal cortex (mm; 
mean±SD) 
2.64 (±0.06) 2.70 (±0.07) >0.10 +2.3 
Entorhinal cortex (mm; 
mean±SD) 
3.15 (±0.09) 2.83 (±0.1) >0.10 -10.2 
Fusiform cortex (mm; mean±SD) 2.60 (±0.04) 2.43 (±0.05) 0.04 -6.5 
Caudal anterior cingulate cortex 
(mm; mean±SD) 
2.57 (±0.04) 2.60 (±0.05) >0.10 +1.2 
Rostral anterior cingulate cortex 
(mm; mean±SD) 
2.76 (±0.04) 2.82 (±0.05) >0.10 +2.2 
Caudate (mean±SD) 2.27 (±0.05) 2.05 (±0.06) 0.02 -9.7 
Putamen (mean±SD) 3.16 (±0.08) 2.98 (±0.09) >0.10 -5.7 
Globus pallidum (mean±SD) 0.94 (±0.02) 0.95 (±0.02) >0.10 +1.1 
Hippocampus (mean±SD) 2.77 (±0.06) 2.55 (±0.07) 0.04 -7.9 
Nucleus accumbens 
(mean±SD) 
0.55 (±0.03) 0.28 (±0.03) 0.001 -49.1 
Amygdala (mean±SD) 1.03 (±0.03) 0.90 (±0.03) 0.03 -12.6 
All the volumes are normalized by intracranial volume and multiplied by 1,000, thus dimensionless. *P 
values are Bonferroni corrected. 
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Structural changes: comparisons within Parkinson’s patients 
Since PD patients with ICDs had significant longer disease duration (P=0.02) and higher 
UPDRS-III scores (P<0.01) than PD patients without ICDs we investigated differences 
in MRI measures between PD patients with and without ICDs using disease duration 
and UPDRS-III score as covariates (F1,32=2.97, P=0.02, η2p =0.737). We found that Cth 
of rostral anterior cingulate cortex (P=0.002) and frontal pole (P=0.001) were thicker 
in PD patients with ICDs compared to the group of PD patients without ICDs (Fig. 6.2.1; 
Table 6.2.4).  
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Table 6.2.4: .Cortical thickness and subcortical nuclei volume in PD patients with ICDs compared to the 
group of PD patients without ICDs.  
 PD without ICDs PD with ICDs 
P 
values* 
% Change (PD ICD 
vs PD not ICD) 
Medial orbitofrontal cortex (mm; 
mean±SD) 
2.17 (±0.04) 2.24 (±0.04) >0.10 +3.2 
Lateral orbitofrontal cortex (mm; 
mean±SD) 
2.43 (±0.05) 2.52 (±0.05) >0.10 +3.7 
Frontal pole (mm;  mean±SD) 2.53 (±0.06) 2.70 (±0.06) 0.001 +6.7 
Superior frontal cortex (mm; 
mean±SD) 
2.51 (±0.05) 2.54 (±0.05) >0.10 +1.2 
Rostral middle frontal cortex (mm; 
mean±SD) 
2.22 (±0.04) 2.29 (±0.04) >0.10 +3.2 
Parahippocampal cortex (mm; 
mean±SD) 
2.53 (±0.07) 2.70 (±0.07) >0.10 +6.7 
Entorhinal cortex (mm; mean±SD) 2.92 (±0.1) 2.83 (±0.1) >0.10 -3.1 
Fusiform cortex (mm; mean±SD) 2.55 (±0.05) 2.43 (±0.05) >0.10 -4.7 
Caudal anterior cingulate cortex (mm; 
mean±SD) 
2.44 (±0.05) 2.60 (±0.05) >0.10 +6.6 
Rostral anterior cingulate cortex (mm; 
mean±SD) 
2.64 (±0.05) 2.82 (±0.05) 0.002 +6.8 
Caudate (mean±SD) 2.10 (±0.06) 2.05 (±0.06) >0.10 -2.4 
Putamen (mean±SD) 3.11 (±0.09) 2.98 (±0.09) >0.10 -4.2 
Globus pallidum (mean±SD) 0.93 (±0.02) 0.95 (±0.02) >0.10 +2.2 
Hippocampus (mean±SD) 2.59 (±0.07) 2.55 (±0.07) >0.10 -1.5 
Nucleus accumbens (mean±SD) 0.32 (±0.03) 0.28 (±0.03) >0.10 -12.5 
Amygdala (mean±SD) 0.99 (±0.03) 0.90 (±0.03) >0.10 -9.1 
All the volumes are normalized by intracranial volume and multiplied by 1,000, thus dimensionless. *P 
values corrected for disease duration and UPDRS-III. 
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The difference between the PD groups in total daily LED was not significant although 
it was considerable (Table 6.2.1), therefore we further calculated an additional 
MANCOVA including total daily LED, disease duration and UPDRS-III score as 
covariates (F1,31=2.81, P=0.02, η2p=0.74). This analysis confirmed our previous findings. 
Cth of rostral anterior cingulate cortex (P=0.002) and frontal pole (P=0.001) were 
thicker in PD patients with ICDs compared to the group of PD patients without ICDs. 
Further, covarying for age did not influence results. The linear regression analyses split 
by group between Cth of rostral anterior cingulate cortex and total daily LED and Cth 
of frontal pole and total daily LED were not significant in both groups. 
No significant differences were found in clinical and morphometric data between PD 
patients with one ICDs and PD patients with multiple ICDs. 
 
  
                                         C. Pellicano – Neuropsychiatric and Cognitive symptoms in PD 
 
 
 ______ 
  153 
 
Figure 6.2.1: Cortical thickness differences between PD patients with and without impulse control 
disorders. 
 
For display purpose only, we have visualized our results using the whole brain GLM analysis provided by qdec. Given 
the aim of the figure, FDR and Montecarlo correction were not applied. The figure shows sagittal section of cortical 
areas with significant increased cortical thickness (i.e, rostral anterior cingulate, left side; frontal pole, right side) 
between PD patients with and without ICDs corrected for disease duration and UPDRS-III score. Difference maps 
are shown via a pseudo-color statistical overlay where black represents p 0.1 and yellow p 0.001. Red and yellow 
indicate thicker cortex in PD patients with ICDs with respect to patients without ICDs. 
 
6.2.4 Discussion 
Our findings demonstrate structural alterations in mesocortical and limbic reward-
related areas including volume loss in ventral striatum, hippocampus and amygdala, 
and increased thickening of anterior cingulate (Brodmann Area-BA 32) and frontal 
pole (part of BA 10) cortices in PD patients with ICDs. 
Indeed, we demonstrate significant volumetric differences in several regions within the 
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reward pathways, which reached corrected levels of statistical significance in PD ICD 
patients compared to healthy controls. We speculate that subcortical alterations in PD 
patients with ICDs may constitute a predisposing neural trait linked to impulsivity. 
Volumetric reductions in the accumbens and amygdala have previously been described in 
individuals at increased genetic risk for addiction [35] or with high levels of trait impulsivity 
[36] and a recent study of rats bred to be highly impulsive found volume reductions in the 
nucleus accumbens [26].  Alternatively, our findings might reflect the expression of 
secondary rearrangements of mesocorticolimbic system including derangement of deep 
gray matter nuclei and subsequent cortical remodeling. Indeed, a recent study in mice 
found that neural sensitization following repeated exposure to cocaine resulted in volume 
reductions in striatum and amygdala [29]. 
It is of interest that we found increased cortical thickness in specific frontal cortical 
areas, in particular rostral anterior cingulate and frontal polar cortex. While these 
increases in thickness may be related to a pre-existing neurobiological trait making 
subjects with thicker cortex more impulsive [37], they may also be secondary to 
neuroplastic adaptations associated with non-physiological dopaminergic stimulation 
occurring only in subjects with increased susceptibility to neural sensitization. 
Levodopa-induced increases in dorsal striatal dopamine release found in PD patients 
with ICDs are observed in PD patients with levodopa-induced dyskinesia (LIDs) [38]. 
Although LIDs and ICDs may occur under different clinical conditions, abnormal 
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behaviours in ICDs might parallel involuntary movements of LIDs as part of a 
pathological spectrum influenced by chronic non-physiological dopaminergic 
transmission and as results of similar form of neural sensitization operating on 
different brain systems [39]. Increased synaptic levels of dopamine and post-synaptic 
modifications such as changes in proteins and genes might determine an aberrant 
increase in the dendritic arborization, neuronal sprouting and neuropil and result in 
maladaptive synaptic plasticity [40-44]. In our study, we found increased thickness in 
medial frontal cortical areas involved in reward valuation and decision-making and we 
speculate that maladaptive synaptic plasticity occurring in these cortical areas could 
result in the behavioural manifestations of ICDs.  
We also acknowledge the limitations of our study. The relative small sample size did 
not allow specific analysis of different variants of ICDs and a comprehensive 
neuropsychological and psychiatric evaluation was not performed on every patient. 
Moreover, we didn’t perform a scale providing severity score for each ICDs and this 
has hampered correlation analysis between morphometric data and ICDs severity.  
In conclusion, this study provides evidence of morphological abnormalities in PD 
patients with ICDs. We found increased cortical thickness in cortical regions involved 
in reward valuation and decision-making, as well as reduced volumes of subcortical 
components of reward circuitry. Our results suggest similarities between ICDs and LIDs 
as analogous side effects of non-physiologic chronic dopaminergic stimulation.  
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6.3 Unraveling predictors affecting compliance to MRI in Parkinson’s disease 
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Hereunder we report an excerpt of the study. Full-text of the related article can be 
found at: 
https://www.ncbi.nlm.nih.gov/pubmed/26410743 
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6.3.1 Background  
MRI is a sensitive, noninvasive and widely available technique for studying PD from 
both research and clinical perspective [45]. Numerous structural or functional MRI 
studies have attempted at clarifying cerebral correlates of motor and non-motor 
symptoms of PD [46]. In clinical setting, structural MRI allows recognition of secondary 
causes of parkinsonism and helps differentiating PD from atypical parkinsonisms [47]. 
Moreover, MRI may contribute at identifying potential biomarkers [48] for the early 
or pre-motor diagnosis of PD and monitoring effects of potentially neuroprotective 
strategies. 
A number of factors (e.g. metal objects, clips, heart pacemaker, etc) may physically 
impede execution of MRI. Moreover, severity of motor and/or non-motor symptoms 
might reduce compliance to MRI by PD subjects.  
This study was aimed at identifying predictors affecting compliance to MRI in PD, in 
order to define the extent to which patients enrolled in MRI studies are representative 
of the whole PD population, and to help precocious identification of subjects requiring 
particular preparation/premedication before undergoing the scan. We predicted that 
patients unable to perform MRI scan would show increased severity of 
neuropsychiatric and cognitive symptoms. 
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6.3.2 Methods 
Two-hundred-thirty-six subjects, diagnosed as having PD according to international 
guidelines [11], were consecutively enrolled during scheduled visits at our Outpatient 
Services for Movement Disorders. They were all under stable and optimized 
dopaminergic therapy for at least 6 months, without need for booster doses of 
levodopa or dopamine agonists. Exclusion criteria were: vision or hearing non-
compliance with procedures;  
1. major not-stabilized medical illnesses;  
2. history of alcoholism, drug dependence or abuse;  
3. head trauma or other neurological disorders (other than PD);  
4. psychiatric disorders (other than mood or anxiety disorder);  
5. H&Y score > 3.  
The study was approved by our Ethical Committee and each participant signed 
informed consent. 
Demographic and neurological features were collected by trained neurologists at 
enrollment. Within 7 days from enrollment, all subjects underwent a SCID-P according 
to the DSM-IV-TR criteria. Patients were then submitted to a complete 
neuropsychiatric and cognitive assessment including: HARS, HDRS, PPRS, ERS, MMSE, 
RIR, RDR, CRO, DRO, SWCT- (interference time and word time), SVF, PVF and WCST-SF 
perseverative errors. 
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Acceptable inter-rater reliability was defined as k>0.80.  
Following these evaluations, patients were submitted to an independent evaluation 
session to identify physical factors preventing execution of the MRI scan and to 
propose and furnish details on MRI procedure. Patients were then divided into 3 
groups according to their compliance to MRI as expressed during the MRI evaluation 
session: 42 patients had physical incompatibility to MRI (PI), including metallic clips 
(n=22), severe kyphosis (n=10), heart pace-maker (n=3), severe dyskinesia (n=3), 
retinic or cervix uteri cerclages (n=2) and orthopedic implant (n=2); 51 patients 
refused (RR) to undergo the scan; 143 patients accepted to undergo and successfully 
performed MRI (SP).  
Statistical Analysis 
A series of univariate analyses of variance (ANOVAs) were used to assess differences 
in continuous variables (demographic, neurological, neuropsychiatric and 
neuropsychological) among groups. Bonferroni’s post-hoc comparisons were 
performed for those variables showing statistically significant differences at ANOVAs. 
To minimize the likelihood of type I errors, ANOVAs were preceded by overall 
multivariate analysis of variance (MANOVA) using all neuropsychiatric and 
neuropsychological test scores as dependent variable. To identify predictors of 
compliance to MRI scan in the whole PD sample (i.e., SP+RR+PI), a logistic regression 
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analysis was carried out considering ability (i.e., SP) or inability (i.e., RR+PI) to undergo 
the scan as dependent variable and parameters showing significant (p<0.05) ANOVA 
differences among three groups as potential predictors.  
 
6.3.3 Results 
PI subject were significantly older, had higher UPRDRS-III score and received lower 
daily dopamine agonist doses that SP (Table 6.3.1). 
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Table 6.3.1. Demographic, clinical and neurological features of the study cohort 
 
PI 
(n=42) 
Mean ± 
SD 
RR 
(n=51) 
Mean ± 
SD 
SP 
(n=143) 
Mean ± 
SD 
F df P 
Post Hoc analysis 
P 
PI vs. 
RR 
P 
PI vs. 
SP 
P 
RR vs. 
SP 
Age (Years) 69.3±8.7 67.5±9.2 65.5±9.1 3.154 2 0.045* 0.997 0.053* 0.553 
Age at onset 
(Years) 
63.1±8.7 62.5±9.5 59.7±9.8 2.936 2 0.055 1.000 0.138 0.215 
Disease 
duration 
(Years) 
6.2±5.6 4.9±4.0 5.8±4.6 1.010 2 0.366 0.528 1.000 0.782 
Education 
(Years) 
10.2±5.0 9.7±4.4 10.3±4.3 0.424 2 0.655 1.000 1.000 1.000 
H&Y score 2.0±0.7 1.7±0.6 1.8±0.5 2.689 2 0.070 0.070 0.221 0976 
UPDRS-III 
score 
23.6±11.9 18.3±13.1 18.0±10.9 3.914 2 0.021* 0.089 0.019* 1.000 
Daily 
Levodopa 
(mg) 
395±459 247±225 307±290 2.559 2 0.080 0.075 0.334 0.738 
Daily 
Dopamine 
Agonist 
Equivalents 
(mg) 
130±158 153±163 227±250 4.238 2 0.016* 1.000 0.039* 0.125 
Daily 
Levodopa 
Equivalents 
(mg) 
525±458 400±240 533±404 2.328 2 0.100 0.364 1.000 0.105 
PI=physical incompatibility; RR=refused; SP=successfully performed; SD=standard deviation; df=degrees of 
freedom; H&Y=Hoehn and Yahr scale; UPDRS-III= Unified Parkinson's Disease Rating Scale – part III; *Statistically 
significant differences. 
 
The MANOVAs carried out using neuropsychiatric and neuropsychological test scores 
as dependent variable indicated a significant global effect of groups (Wilks’ lambda = 
0.782; F = 1.909; df = 30, 438; p = 0.0031) on neuropsychiatric and neuropsychological 
performances.  
Differences among the three PD groups in clinical characteristics are shown in Table 
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6.3.2. In particular, PI patients displayed significantly lower global cognition score and 
worse performances at several neuropsychological domains as compared to SP (Table 
6.3.2). RR subjects had significantly higher anxiety score, as measured by the HARS, 
than SP. Both patient groups non undergoing MRI (PI and RR) had lower quality of life 
score than SP (Table 6.3.2).  
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Table 6.3.2: Neuropsychiatric and neuropsychological features of the study cohort 
 
PI 
(n=42) 
Mean ± SD 
RR 
(n=51) 
Mean ± 
SD 
SP 
(n=143) 
Mean ± SD 
F df P 
Post Hoc analysis 
P 
PI vs. 
RR 
 
P 
PI  
vs. SP 
 
P 
RR vs. 
SP 
 
HARS 9.3±7.4 10.8±6.0 7.3±4.8 8.089 2 0.000* 0.574 0.130 0.000* 
HDRS 8.3±5.7 8.8±5.2 7.3±4.6 1.868 2 0.157 1.000 0.837 0.212 
PPRS Total 6.8±1.0 7.0±1.2 6.8±1.2 0.502 2 0.606 1.000 1.000 1.000 
ERS Total 7.4±1.8 7.3±1.6 7.1±1.4 0.687 2 0.504 1.000 0.936 1.000 
MMSE 26.7±3.0 27.5±3.2 28.0±2.1 4.663 2 0.010* 0.465 0.010* 0.504 
RIR 29.3±11.2 35.6±12.5 35.0±10.3 4.923 2 0.008* 0.019* 0.011* 1.000 
RDR 5.6±3.4 6.8±3.6 7.2±3.4 3.577 2 0.030* 0.293 0.024* 1.000 
CRO 25.1±7.5 26.3±7.6 27.9±5.8 3.466 2 0.033* 1.000 0.043* 0.404 
DRO 12.4±6.4 14.3±6.0 15.1±6.2 3.205 2 0.042* 0.379 0.036* 1.000 
SWCT 
interference 
time 
57.7±34.6 47.9±17.7 49.0±23.3 2.316 2 0.101 0.174 0.140 1.000 
SWCT word 
time 
20.1±9.3 18.0±6.3 17.9±9.2 1.072 2 0.344 0.773 0.453 1.000 
SVF 15.2±5.8 17.1±5.5 18.4±5.6 5.225 2 0.006* 0.304 0.005* 0.560 
PVF 26.3±12.1 27.7±13.0 30.0±11.0 1.915 2 0.150 1.000 0.225 0.684 
WCST-SF 
perseverative 
errors 
7.7±9.5 6.8±9.9 4.4±6.3 3.651 2 0.027* 1.000 0.059 0.189 
PI=physical incompatibility; RR=refused; SP=successfully performed; SD=standard deviation; df=degrees of 
freedom; HARS=Hamilton Anxiety Rating Scale; HDRS=Hamilton Depression Rating Scale; PPRS=Parkinson Psychosis 
Rating Scale; ERS=Euro-QoL Scale; ; MMSE=Mini Mental state Examination; RIR=Rey’s 15-word test – Immediate 
Recall; RDR=Rey’s 15-word test – Delayed Recall; CRO=Copy of the Rey-Osterrieth picture; DRO=Delayed Recall of 
the Rey-Osterrieth picture; SWCT=Stroop Word-Color Test; SVF=Semantic Verbal Fluency; PVF=Phonologic Verbal 
Fluency; WCST-SF=Wisconsin Card Sorting Test – short form. 
 *Statistically significant differences. 
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Based on the results of ANOVAs, we included as predictors in the logistic regression 
analysis the following variables: age; UPDRS-III score; daily dopamine agonist 
equivalent dose; HARS score; RIR score; CRO score; SVF score and WCST-SF 
perseverative errors. MMSE was not included being an index of global cognitive 
functioning. As to the memory domain, RDR and DRO scores were excluded because 
they showed lower statistical power compared with RIR score. Among potential 
predictors for lack of compliance with MRI in the whole PD sample (i.e., SP+RR+PI), 
only lower daily dopamine agonist equivalents (p=0.021) and higher score for anxiety 
(p=0.013) reached statistical significance. 
 
6.3.4 Discussion 
MRI gained high relevance in both research and clinical setting. PD patients may, 
however, suffer from several conditions preventing execution or completion of MRI 
scan, therefore research and clinical activities based on MRI findings may be affected 
by a significant selection bias. The purposes of the present study were to clarify to 
which extent PD patients undergoing MRI scan are representative of the whole PD 
population, and to guide clinicians in identifying variables that make patients 
incompliant to the exam. Our results show that several clinical, neuropsychological 
and neuropsychiatric features differentiate among PI, RR and SP patients. These 
findings suggest that research studies aimed at identifying cerebral alterations 
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associated with cognitive impairment in PD by MRI may suffer from biases of excluding 
more severely affected subjects. Indeed, RR patients displayed significantly higher 
severity of anxiety than SP. The present results support the hypothesis that brain MRI 
studies aimed at identifying the structural and functional alterations underpinning 
neuropsychiatric symptoms in PD cohorts (in particular anxiety) may exclude patients 
with more severe neuropsychiatric involvement. 
Higher score for anxiety and lower daily doses of dopamine agonists were the unique 
significant predictors of inability to undergo MRI scan. These two factors may, indeed, 
be reciprocally related as dopamine agonists may exert therapeutic efficacy on 
symptoms of anxiety in PD patients [50]. 
In conclusion, the present results contribute defining motor and non-motor features 
of compliance to closed bore MRI by PD patients and provide valuable aid for setting 
and interpreting structural and functional MRI research studies in PD. Moreover, the 
identification of predictors of noncompliance to MRI may help clinicians to tailor 
psychological and/or pharmacological strategies helping patients to complete the 
exam. 
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7. Conclusions 
The prevalence of PD and thus the burden of associated neuropsychiatric and 
cognitive symptoms will increase in future years due to blatant trends in the age-
structure of populations. Rising age in the general population often equates to an 
increase in co-morbidities and associated polypharmacy. Therefore, the detection and, 
if possible, prevention, of neuropsychiatric and cognitive symptoms associated with 
PD is of highest importance for future generations in terms of healthcare costs, social 
care and prevention of morbidity and mortality. Indeed, neuropsychiatric and 
cognitive assessments hence should be included in the routine evaluation of patients 
with PD in order to allow effective management of the patients. In turn, this approach 
can provide the patients and their families with adequate information enabling them 
to formulate a proper planning of their own future needs. 
Following this integrative need, a clinician taking care of a patient suffering from PD 
does not have to treat motor symptoms alone, which belong to the field of neurology, 
but he also has do diagnose and treat affective or cognitive symptoms, which belong 
to the field of psychiatry. This approach attempts to overcome the paradoxical 
situation in the contemporary relationship between neurology and psychiatry. We 
strongly believe that PD may be regarded as a paradigmatic example of 
neuropsychiatric disease in a current gestalt and as an attractive model where the 
boundaries between neurology and psychiatry melt away because of the overlapping 
                                         C. Pellicano – Neuropsychiatric and Cognitive symptoms in PD 
 
 
 ______ 
  173 
 
of shared symptoms. Indeed, the motor action cannot be observed separated from 
affect/emotion and cognition because of the mutually overlapping systems, enabling 
the motor action to influence affect/emotion and cognition directly, and reverse. 
Neuropsychiatric-cognitive and motor alterations in PD should be no longer explained 
separately and independently but regarded as two expressions of a uniform dynamic-
functional structure. It is the alteration of this structure, and not of the two different 
symptom complexes as two different phenomena, that has to be explained. 
The conceptualization and understanding of PD symptoms by the integration of 
neurological and psychiatric knowledge is the leading thread of this research. 
The studies discussed above described the contribution of neuropsychiatric and 
cognitive assessment in different scenarios and in different stages of PD. 
In particular, our results here presented showed that: 
 In untreated PD patients, the body side of onset of motor symptoms does not 
influence the pattern or severity of neuropsychiatric and cognitive 
abnormalities. Nor motor subtypes are associated with a specific cognitive and 
neuropsychiatric profile. These results support the idea that a possible 
cognitive-affective differentiation emerges only with the progression of the 
disease and potentially with its interaction with DRT. 
 In early PD patients, whithin 24 months from the onset of motor symptoms, 
comprehensive cognitive and psychiatric evaluations might be useful and cost-
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effective contributors to the diagnostic work-up of patients with progressive 
parkinsonism. Indeed, verbal fluency impairment and apathy diagnosis are 
more supportive of diagnosis of PSP-RS and PSP-P respectively, rather than PD. 
Further, difficulty in describing feelings could help to identify PSP-RS patients. 
 In advanced PD patients, when the full picture is often complicated by 
interaction with DRT, neuropsychiatric and cognitive assessments are crucial in 
identifying subset of fragile patients. Indeed, we demonstrate different 
neuropsychiatric profiles between PG and ICD-NOS indicating that 
development of PG is linked with significantly more severe depression and 
anxiety, and that development of impulsive/compulsive behaviors occurs 
independently from any selective impairment of cognitive function. To shed 
more light into ICD issue, in a structural MRI study, we demonstrated increased 
cortical thickness in cortical regions involved in reward valuation and decision-
making, as well as reduced volumes of subcortical components of reward 
circuitry in PD patients with ICDs. Finally, defining motor and non-motor 
features of compliance to closed bore MRI by PD patients, our results advice 
clinicians to tailor psychological and/or pharmacological strategies helping 
patients to complete the exam and investigators to set and interpret MRI 
research studies. 
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The results of the current research provide a valuable support in understanding the 
fruitfulness of neuropsychiatric and cognitive symptoms assessment in the diverse 
stages of PD. Nonetheless, yet more efforts have to be made. Certainly, future 
directions urge to include longitudinal evaluation and larger study cohorts to confirm 
the present findings.  
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8. Ancillary Research 
8.1 Phosphorylated α-synuclein immunoreactivity in nerve fibers from minor 
salivary glands in Parkinson’s disease 
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8.1.2 Methods 
Seven patients diagnosed with PD according to the UKPDBB criteria [1] with disease 
duration >3 years and sustained response to dopaminergic therapy, and 7 healthy 
volunteers were recruited. They all signed informed consent. Exclusion criteria for 
both groups were: i. MMSE score <26; ii. Bleeding diathesis; iii. Anticoagulant therapy; 
iv. Systemic disorders contraindicating biopsy; v. Known or suspected salivary gland 
pathology. Under local anesthesia with xylocaine, minor salivary gland biopsy was 
performed and tissue was immediately frozen in paraformaldehyde. There was no 
report of adverse event. 
Tissue sections were cut on the microtome, mounted on electrostatically charged 
glass slides, deparaffinized and rehydrated, then treated with either citrate buffer 
(0.01 mol/L, pH 6) in microwave (750 W) (for α-synuclein) or proteinase K in phosphate 
buffered saline pH 7.0 (37°C, 20 minutes) (for Ser129-phosphorylated-α-synuclein). 
Three consecutive tissue sections were obtained at 3 different levels from each biopsy. 
For each triplicate, sections were incubated with either mouse monoclonal anti-α-
synuclein (code LB509, Zymed Laboratories, Invitrogen, 1:200, 1h, RT), mouse 
monoclonal anti-Ser129-phosphorylated-α-synuclein (code pSyn#64, Wako, Japan, 
1:1000, 1h, RT), or rabbit policlonal anti-S100 (code Z311, Denmark, 1:300, 1h, RT), 
respectively. The reaction was amplified with LSAB2+System-HRP (Dako, CA, USA). 
Positive immunoreaction was identified after incubation with 3,3’-diaminobenzidine 
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(DAB) and counterstaining with Mayer hematoxylin. Negative controls were obtained 
omitting the primary antibodies. 
Immunostaining was quantified on 5-Mp (24-bit color depth) images (400x 
magnification) from all sections of each salivary gland (mean area 13,888,121.35 μm2) 
(ImageJ software, NIH, USA). For each sample, immunostaining was expressed as the 
mean positive area normalized to the total area of the examined section, and 
expressed as the ratio between areas. Values for α-synuclein and Ser129-
phosphorylated-α-synuclein were also normalized to the S100 value indicative of the 
presence of nerve fibers in the examined gland and expressed as the ratio between 
areas. Data were expressed as means±SEM. The results were analyzed with the 
Student’s t-test, threshold for significance being set at p<0.025. 
 
8.1.3 Results 
The ratio of nerve fibers immunoreactive to α-synuclein (α-synuclein+/S100+ ratio) was 
not significantly decreased in PD patients compared with healthy subjects 
(0.039±0.046 vs. 0.149±0.030; p>0.025).  
Conversely, Ser129-phosphorylated-α-synuclein immunoreactive nerve fibers 
(Ser129-phosphorylated-α-synuclein+/S100+) were identified in 5/7 PD cases 
(0.004±0.006) but never in control subjects (p<0.025) (Fig 8.1). Immunostaining was 
found also in the cytoplasm of some acini and ductule cells from subjects belonging to 
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both groups; rarely, secretory material within ductules was also stained. 
 
 
Fig 8.1. Panel A. Representative photomicrographs (original magnification x40) of salivary gland tissue showing 
very thin nerve fibers immunostained with alpha synuclein (thin arrow) and Ser129-phosphorylated-a-synuclein 
(thick arrow) in PD patients and healthy subjects. Panel B. Immunostaining quantification of alpha synuclein and 
Ser129-phosphorylated-a-synuclein in PD and healthy subjects. The graphics show immunostaining for Ser129-
phosphorylated-a-synuclein/S100 (*p < 0.025) only in in PD together with reduced immunostaining for a-
synuclein/S100 compared to healthy subjects. 
 
8.1.4 Discussion 
Accuracy of clinical diagnosis of PD ranges between 50 and 90%, prolonged clinical 
observation and response to dopaminergic therapy being the most reliable markers 
[1]. Identification of biomarkers supporting PD diagnosis early along disease course is, 
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therefore, of great interest. Interestingly, Ser-129-phosphorylated-α-synuclein is a 
biochemical hallmark of PD and other Lewy body disorders, not detectable by 
immunohistochemistry in normal neural tissue [3]. Nerve fibers immunoreactive to 
Ser129-phopshorylated-α-synuclein have been reported previously in submandibular 
gland biopsies from PD patients [2,3]. Despite the potential advantage of being a less 
invasive procedure, minor salivary gland biopsy failed to provide sufficient sensitivity 
in previous studies [3,4]. 
Differently from those previous reports [3,4], we applied semi-quantitative analysis for 
identifying immunostaining with monoclonal anti-Ser129-phopshorylated-α-synuclein 
antibody in nerve fibers from minor salivary gland biopsies in PD patients but not 
healthy controls. This was accompanied by reduced immunostaining for α-synuclein 
in nerve fibers from PD patients, as if abnormal phosphorylation of α-synuclein would 
occur in peripheral nerve fibers in the minor salivary glands in the majority of PD cases. 
Finally, the immunostaining for α-synuclein in acini and ductule cells and the 
identification of immunostaining in secretory material within ductules may be of 
interest for the recent report of abnormal salivary total and oligomeric α-synuclein in 
PD [5]. 
In conclusion, the results of this pilot study suggest that semi-quantitative measurement of 
immunoreactivity to α-synuclein and Ser129-phosphorylated-α-synuclein may discriminate 
PD patients from healthy controls. If confirmed on larger series, this approach might 
                                         C. Pellicano – Neuropsychiatric and Cognitive symptoms in PD 
 
 
 ______ 
  181 
 
provide a useful, poorly invasive, support to the clinical diagnosis of PD. 
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8.2 The PD-Manager Project: m-health platform for Parkinson’s disease 
management. Project overview 
 
http://www.parkinson-manager.eu/ 
 
“PD-Manager: mHealth platform for Parkinson's disease” is an international project 
Co-funded by the European Union’s Horizon 2020 Framework Programme for 
Research and Innovation under Grant Agreement No 643706. 
The study will be coordinated by the Jožef Stefan Institute in Ljubljana while the 
technical aspects will be supervised by the Biomedical Engineering Department of the 
University of Ioannina. The clinical partners are the IRCCS San Camillo Hospital of 
Venice, IRCCS Santa Lucia in Rome (Neuropsychiatry Laboratory, Department of 
Clinical and Behavioral Neurology), the Neurology Clinic of the University Ioannina 
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(Greece) and the rehabilitation Centre University of Ljubljana (Slovenia). 
After the definition of user needs under the coordination of the psychology unit of the 
University of Surrey, the project will involve in the pilot phase, 30 patients and, at the 
end of 2016, it will become one of the largest multi-centre studies involving a total of 
230 patients across four European centres. During the stages of advancement, updates 
will be provided with live demonstrations of the achievements, to all the countries 
involved utilising the power of the web. Furthermore, the technologies that will result 
will be made available to all. The project partners are please to have the support of 
the European Parkinson Disease Association (EPDA) who will help in the trans-national 
dissemination of results. 
The PD_manager project aims to: 
 Propose a set of unobtrusive, simple-in-use, co-operative, mobile devices that 
will be used for symptoms monitoring and collection of adherence data 
(smartphone, sensor insole, wristband with several sensors for acceleration, 
heart rate, etc.). 
 Model the behaviors of intended users of PD_manager (patients, caregivers, 
neurologists and other health-care providers). 
 Educate patients, caregivers and healthcare providers with the focus on 
occupational and speech therapies 
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A smart watch, an insole to measure gait and balance, an electronic pillbox and a set 
of applications for smartphone, will enable a medical team to monitor and assess the 
motor, emotional and cognitive state of people with PD during their daily life at home. 
With the support of a powerful server and online data collection system, it will be 
possible to provide each patient the specific therapeutic changes necessary to ensure 
the best treatment and develop rehabilitation focused home-care system that will 
improve quality of life and reduce the risk of complications including falls. 
The project, started in January 2015, is now in its final phase and we are 
gathering data from 230 patients. 
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Fig.8.2: Dashboard of the insole mesaurements 
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8.3 The PICASO Project: A Personalized Integrated Care Approach for Service 
Organizations and Care Models for Patients with Multi-Morbidity and Chronic 
Conditions. Project overview 
 
 
 
http://www.picaso-project.eu/ 
 
The “Personalized Integrated Care Approach for Service Organizations and Care 
Models for Patients with Multi-Morbidity and Chronic Conditions.-PICASO project” is 
an international project Co-funded by the European Union’s Horizon 2020 Framework 
Programme for Research and Innovation under Grant Agreement No 689209. 
The PICASO project aims to develop an ICT platform which will support the 
coordination of care plans across different sectors for people diagnosed with co-
occurring chronic diseases. The PICASO project addresses three main challenges in 
Europe’s healthcare systems:  
                                         C. Pellicano – Neuropsychiatric and Cognitive symptoms in PD 
 
 
 ______ 
  188 
 
 managing multi-morbidities;  
 coordinating care and treatment across organizational silos 
 adapting ehealth solutions to existing care models and plans. 
The technologies will be trialed in a German and an Italian setting. In Germany, the 
University Hospital of Düsseldorf will involve their patients diagnosed with 
Rheumatoid Arthritis. In Italy, the University Hospital of Tor Vergata in Rome, in 
collaboration with Neuropsychiatry Laboratory Department of Clinical and Behavioral 
Neurology of IRCCS Santa Lucia Foundation, engage patients with PD. Both patient 
groups have Cardiovascular Diseases and/or other co-morbidities. 
The technology 
The PICASO platform is a service oriented, ICT based integration platform based on 
dynamic and personalized orchestration of care services. The method for sharing 
patient information between all relevant formal and informal care providers is by 
using a unique, trust federated solution, thereby overcoming the problem of data 
privacy in cloud based health systems. . Each patient will be monitored at home with 
a smart wristband collecting data about heart rate, sleep quality and daily steps 
covered. Futher, therapy reminder tool and blood pressure measurement instrument 
is provided. 
The platform contains an Integrated Care Platform, a Data Management Platform and 
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a Multi-Morbidity Decision Tool. 
The PICASO Integrated Care Platform: 
 is an integration platform for sharing a patient’s complete care pathways 
across multi-actor care spaces.The Platform, with appropriate tools such as risk 
prediction models for the interpretation of patients’ immediate and future 
health status, the ability to dynamically adjust the content and management 
of the delivered care services, is so always adapted to the patient’s personal 
health status and ability. 
 Contains a robust, privacy compliant, cloud based Resource Management 
system that can perform acquisition of physiological and behavioural data in 
non-clinically controlled care spaces, taking into account the variability in the 
population to provide carers with realistic situational awareness. 
 Creates a new approach to integrated care based on the concepts of dynamic 
service narratives that define the workflow (content and management of care 
services) to be launched and orchestrated across the relevant care spaces. 
 Provides decision support for multi-actor interaction and enables patients and 
relatives to become active participants. 
The PICASO Data Management Platform: 
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 Provides role-based access for carers to distribute shared data and exchange 
of knowledge about the patient’s status in an intuitive collaborative platform. 
 Provides a framework for secure, privacy compliant, and role-based 
information sharing through a common view of data allowing carers to control 
and share patient information and exchange knowledge across care networks 
using intuitive, interactive ad-hoc information search. 
The PICASO Multi-Morbidity Decision Support Tool: 
 Contains a decision support methodology for analyzing conflicts, constraints 
and limitations from single-morbidity care plans and 
patient/physician/therapist preferences applied to patients with comorbidities 
and multi-morbidity conditions by using the concept of constraint satisfaction 
problem, to allow the cares to define new care programs for the management 
of co-morbidities in community and home care settings. 
 Forms the basis for new training programs for the care workforce, new 
organizational models and new ways of exchanging medical information to 
improve the coordination of multi-morbidity care management across silos. 
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Fig 8.3 Clinician Dashboard showing the integrated health care net. 
 
 
 
 
Fig 8.4 Clinician Dashboard showing the collected mesaurments. 
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